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Abstract
The increased sophistication of non-standard radiotherapy techniques have encouraged the development of precise, accurate and fast dosimetry systems for treatment
verification. For eye plaque dosimetry verification, the Centre for Medical Radiation
Physics (CMRP) have previously designed a diode based spectroscopic probe. This
research aims at improving the original design by increasing the spatial resolution,
reducing the angular dependence and minimising the distance between eye plaque
and the detector sensitive volume.
GEANT4 simulations were used as a verification of the construction of the redesigned probe, with the average variation of the probes response to that of absorbed
dose to water of ± 1.78% for clinically applicable depths. A custom 3D-printed phantom was designed to facilitate sterile measurements whilst achieving an approximate
water environment necessary for TG-43 U1 validity. Furthermore, it included a number of separate pieces and compartments designed to separate the sterile plaque and
seeds from the water bath.
Experimentally, the accuracy of the new probes design and response utilising the
3D-printed water phantom in conducting spectroscopic, eye plaque brachytherapy
dosimetry was ± 2% compared to the projected dose rates calculated using the
clinical Treatment Planning System (TPS). It was also successful in identifying seed
packing errors, introduced into the plaque to test its dose rate response sensitivity.
The spectroscopic dosimetry system has been verified for use in the clinical
environment as an eye plaque brachytherapy QA tool and can be used for pretreatment verification of dose-rate.

iii

Acknowledgments
I would like to thank the multitudes of people that have helped to make this thesis
happen. Firstly, my supervisor Dr. Dean Cutajar, thank you for all of the hard work
and effort you put into the making of this thesis, I appreciate all of your support. My
technical support Dr. Michael Weaver, your expertise is making things automatic
and for introducing me to the world of 3D printing was so much appreciated. I would
like to thank both of you for your continuous hard work and for the opportunities
you provided. I believe that your tutelage and guidance has made me into a better
physicist!
I would like to thank Distinguised Professor Anatoly Rosenfeld for establishing
this project and offering wisdom and advice into its progression. In addition to
whole CMRP, both staff and students, in particular the most helpful Karen. It
was a fantastic opportunity and a privilege to work as a part of one of an eminent
Medical Physics research organisation, I am extremely grateful. A big thanks also
goes to Dr. Susanna Guatelli for her Geant4 strategies and support, and to Dr.
Marco Petasecca for sharing your unrivalled detector knowledge. I’d like to extend
a huge thank you to Alex Pogossov for the development of the projects electronics.
In addition, I would like to thank and acknowledge the folk working on the
UOW HPC (High Performance Cluster) network. Their high powered and fast
processing, along with timely technical support was invaluable to my GEANT4
simulation work. I have to extend a huge thank you to Simon Downes and the
collaboration of the Nelune Cancer Care Centre, Prince of Wales Hospital, Randwick
for their collaboration on the project. In particular, I would like to thank Claire

iv

Pagulayan and Paul White for their help in preparing and carrying out experiments,
and for absorbing the lions share of radiation in doing so.
To Lachlan Chartier, thank you for your help in realising my designs with your
superior technical drawing skills. I also would like to thank you for your persistent
encouragement and for being able to make me laugh in the midst of a scientific crisis.
I’d like to thank my family for supporting me both emotionally and financially, for
putting no time-limit on my education and for making the rest of my life as simple
and as easy as was possible.
This research has been conducted with the support of the Australian Government Research Training Program Scholarship.

v

List of Figures
2.1

The Eye . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

4

2.2

Diagram of ROPES Eye Plaque . . . . . . . . . . . . . . . . . . . . .

9

2.3

Diagram of Brachytherapy Seed . . . . . . . . . . . . . . . . . . . . . 10

2.4

Picture of ROPES Eye Plaque . . . . . . . . . . . . . . . . . . . . . . 12

2.5

TG-43U1 Formalism . . . . . . . . . . . . . . . . . . . . . . . . . . . 17

2.6

Internal Structure of Brachytherapy Seeds . . . . . . . . . . . . . . . 18

2.7

Rayleigh Scattering . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20

2.8

Photoelectric Effect . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21

2.9

Compton Scattering

. . . . . . . . . . . . . . . . . . . . . . . . . . . 23

2.10 Electron Collisions . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
2.11 Bremsstrahlung . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
2.12 Mass Absorption Coefficient of Water and Silicon . . . . . . . . . . . 29
2.13 Semi-conductor Bands . . . . . . . . . . . . . . . . . . . . . . . . . . 29
2.14 Junction of Semiconductor Material . . . . . . . . . . . . . . . . . . . 31
2.15 I-125 Spectrum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
2.16 Clipped Signal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.17 Original Eye Plaque Probe . . . . . . . . . . . . . . . . . . . . . . . . 41
2.18 Read-out Unit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
3.1

Single Experimental Set-up

. . . . . . . . . . . . . . . . . . . . . . . 44

3.2

Single Seed Calibration . . . . . . . . . . . . . . . . . . . . . . . . . . 45

3.3

Full Plaque Measurement . . . . . . . . . . . . . . . . . . . . . . . . . 46

3.4

Plaque Rings Diagram . . . . . . . . . . . . . . . . . . . . . . . . . . 47
vi

3.5

Inner Ring of Seeds Depth-Dose . . . . . . . . . . . . . . . . . . . . . 48

3.6

Outer Ring of Seeds Depth-Dose . . . . . . . . . . . . . . . . . . . . . 49

3.7

Incident Photon Angles . . . . . . . . . . . . . . . . . . . . . . . . . . 50

4.1

Motorised Gantry Drawing . . . . . . . . . . . . . . . . . . . . . . . . 53

4.2

Motorised Set-Up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54

4.3

Full Plaque Depth-Dose Using Motorised Set-Up . . . . . . . . . . . . 55

4.4

Inner-Ring of Seeds Depth Dose Using Motorised Set-Up . . . . . . . 56

4.5

Outer-Ring of Seeds Depth Dose Using Motorised Set-Up . . . . . . . 57

5.1

Edgless Diode Diagram . . . . . . . . . . . . . . . . . . . . . . . . . . 60

5.2

NN1 IV Characteristics . . . . . . . . . . . . . . . . . . . . . . . . . . 61

5.3

NN2 IV Characteristics . . . . . . . . . . . . . . . . . . . . . . . . . . 62

5.4

PN IV Characteristics . . . . . . . . . . . . . . . . . . . . . . . . . . 63

5.5

NN Spectra . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64

5.6

PN Spectra . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64

5.7

Depletion of Edgeless Diode . . . . . . . . . . . . . . . . . . . . . . . 65

5.8

PCB Dimensions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67

5.9

Edgeless Detector Position . . . . . . . . . . . . . . . . . . . . . . . . 68

5.10 3D-printed probe casing . . . . . . . . . . . . . . . . . . . . . . . . . 69
5.11 Photo of the new probe . . . . . . . . . . . . . . . . . . . . . . . . . . 70
5.12 PCB Wiring . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
6.1

Geant4 Simple Model . . . . . . . . . . . . . . . . . . . . . . . . . . . 72

6.2

Comparison of Geant4 with TG-43 U1 in Spectrum and Calculated
Dose . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73

6.3

Comparison of water Geant4 and TG-43 U1 . . . . . . . . . . . . . . 74

6.4

Geant4 model of PCB and plaque, visualised . . . . . . . . . . . . . . 75

6.5

Comparison of Geant4 model of PCB and water silicon volume . . . . 76

6.6

Comparison of Geant4 spectrum compared to an experimental spectrum 77

6.7

Visualisation of new probe . . . . . . . . . . . . . . . . . . . . . . . . 78

vii

6.8

Comparison of new probe and water volume . . . . . . . . . . . . . . 79

6.9

Comparison of new probe without a nickel coating and water volume

80

6.10 Inner plaque comparison of new probe and water volume . . . . . . . 80
6.11 Inner plaque comparison of new probe without a nickel coating and
water volume . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
6.12 Outer plaque comparison of new probe and water volume . . . . . . . 82
6.13 Outer plaque comparison of new probe without a nickel coating and
water volume . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
7.1

Eye Plaque Phantom . . . . . . . . . . . . . . . . . . . . . . . . . . . 85

7.2

Cross-Section of Eye Plaque Phantom . . . . . . . . . . . . . . . . . . 85

7.3

Phantom Insert . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86

7.4

Single Seed Cap . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87

8.1

Motorised Set-Up with Phantom . . . . . . . . . . . . . . . . . . . . . 89

8.2

New Probe Spectrum . . . . . . . . . . . . . . . . . . . . . . . . . . . 89

8.3

New Probe Calibration . . . . . . . . . . . . . . . . . . . . . . . . . . 90

8.4

New Probe Depth Dose . . . . . . . . . . . . . . . . . . . . . . . . . . 91

8.5

Clinical Strength Calibration . . . . . . . . . . . . . . . . . . . . . . . 93

8.6

Clinical Strength Depth Dose . . . . . . . . . . . . . . . . . . . . . . 94

8.7

Diagram Showing Inner and Outer Seed Positions . . . . . . . . . . . 95

8.8

Introduced Error 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96

8.9

Introduced Error 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97

9.1

CT of New Probe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100

9.2

Cross-section of Probe . . . . . . . . . . . . . . . . . . . . . . . . . . 100

9.3

Cross-sectional Image of Probe Tip . . . . . . . . . . . . . . . . . . . 101

9.4

Cross-sectional Image of Probe Tip with Dimensions . . . . . . . . . 102

9.5

Distance-Corrected Depth Dose . . . . . . . . . . . . . . . . . . . . . 103

9.6

Predicted Depth Dose . . . . . . . . . . . . . . . . . . . . . . . . . . 104

viii

List of Tables
2.1

5 Year Mortality Rates of Ocular Melanoma . . . . . . . . . . . . . .

5

2.2

Oncoseed 6711 I-125 photon spectra . . . . . . . . . . . . . . . . . . . 11

5.1

Edgeless Diode Specifications . . . . . . . . . . . . . . . . . . . . . . 61

5.2

PN Diode Efficiency and Energy Resolution . . . . . . . . . . . . . . 66

9.1

Distance corrections

. . . . . . . . . . . . . . . . . . . . . . . . . . . 105

ix

Contents

Abstract

iii

List of Figures

vi

List of Tables

ix

1 Introduction

1

2 Literature Review

4

2.1

2.2

The Eye . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

4

2.1.1

Ocular Melanoma . . . . . . . . . . . . . . . . . . . . . . . . .

5

2.1.2

Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

6

Brachytherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

7

2.2.1

ROPES Eye Plaque . . . . . . . . . . . . . . . . . . . . . . . .

8

2.2.2

Iodine-125 Brachytherapy Source . . . . . . . . . . . . . . . .

9

2.3

Importance of Quality Assurance . . . . . . . . . . . . . . . . . . . . 11

2.4

TG-43 U1 Protocol . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14

2.5

Photons Interactions . . . . . . . . . . . . . . . . . . . . . . . . . . . 19

2.6

2.7

2.5.1

Elastic Scattering . . . . . . . . . . . . . . . . . . . . . . . . . 19

2.5.2

Energy Deposition Mechanisms . . . . . . . . . . . . . . . . . 20

Electrons Interacting with Matter . . . . . . . . . . . . . . . . . . . . 24
2.6.1

Collisional Interactions . . . . . . . . . . . . . . . . . . . . . . 25

2.6.2

Radiative Interactions . . . . . . . . . . . . . . . . . . . . . . 26

Radiation Detectors . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27

x

2.7.1

Diode detectors . . . . . . . . . . . . . . . . . . . . . . . . . . 28

2.8

Spectroscopic Dosimetry . . . . . . . . . . . . . . . . . . . . . . . . . 32

2.9

Monte Carlo Simulations . . . . . . . . . . . . . . . . . . . . . . . . . 35

2.10 The Eye Plaque Quality Assurance System . . . . . . . . . . . . . . . 40
2.10.1 Eye Plaque Probe . . . . . . . . . . . . . . . . . . . . . . . . . 40
2.10.2 Microprocessor Unit . . . . . . . . . . . . . . . . . . . . . . . 41
3 Testing of the Spectroscopic Eye Plaque Probe

43

3.1

Single Seed Calibration . . . . . . . . . . . . . . . . . . . . . . . . . . 43

3.2

Plaque Measurement . . . . . . . . . . . . . . . . . . . . . . . . . . . 45

3.3

Shallow Depth-Dose Effects . . . . . . . . . . . . . . . . . . . . . . . 47

3.4

3.3.1

The Inner Ring of Seeds Only . . . . . . . . . . . . . . . . . . 47

3.3.2

The Outer Ring of Seeds Only . . . . . . . . . . . . . . . . . . 48

Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51

4 Design and Testing of Motorised Positioning System

52

4.1

Implementation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52

4.2

Full-plaque Tests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53

4.3

Inner-plaque . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55

4.4

Outer-plaque . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57

4.5

Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57

5 Design of the New Probe
5.1

59

Detector . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
5.1.1

I-V Characteristics . . . . . . . . . . . . . . . . . . . . . . . . 61

5.1.2

Spectral Characteristics . . . . . . . . . . . . . . . . . . . . . 63

5.2

Diode Housing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66

5.3

Probe Construction . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69

6 Geant4 Simulations
6.1

71

Verification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71

xi

6.2

PCB Model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74

6.3

New Probe Model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77

6.4

Angular Dependence . . . . . . . . . . . . . . . . . . . . . . . . . . . 81

6.5

Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83

7 Eye Plaque QA System
7.1

84

Eye Plaque Phantom . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
7.1.1

Spectroscopic Eye Probe Calibration Insert . . . . . . . . . . . 87

8 Experimental Measurements

88

8.1

Characterisation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88

8.2

Single Seed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90

8.3

Full Plaque . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91

8.4

Clinical Strength Measurements . . . . . . . . . . . . . . . . . . . . . 92

8.5

Calibration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92

8.6

Full Plaque Measurement . . . . . . . . . . . . . . . . . . . . . . . . . 94

8.7

Introduction of Errors . . . . . . . . . . . . . . . . . . . . . . . . . . 95

8.8

Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97

9 Detector Optimisation

99

9.1

CT Scan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99

9.2

Distance Corrections . . . . . . . . . . . . . . . . . . . . . . . . . . . 103

9.3

Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106

10 Conclusion

107

Bibliography

109

xii

Chapter 1
Introduction
A majority of ocular malignancies occur in the uveal layer of the eye, in the vascular
and melanin rich choroid [1]. The most common of these is choroid melanoma, which
is carcinogenic melanocytes in the choroid and has relatively high mortality rates
which increase with tumour size [2]. For patients with tumours classified as large,
approximately 53% die within 5 years of diagnosis [3].
Historically, the surgical removal of the eye (enucleation) or local resection has
been the primary mode of treatment, eliminating any chance of preserving sight in
the diseased eye. Alternative treatments such as eye plaque brachytherapy are used
as an option to preserve the patient’s eye and retain their sight. This treatment
method involves packing low dose rate brachytherapy seeds into an eye plaque (a
concave, metallic plaque coupled with an acrylic applicator) [4]. This plaque is
attached to the sclera of the patient, such that it covers the base of the tumour, and
remains there for several days. The duration of the treatment is determined by the
dose prescription and the activity of the seeds. The radiation emitted kills the cells
in close proximity to the seeds, while the plaque acts as a shield to protect healthy
tissue, such as the brain and optic nerve. Eye plaque brachytherapy is therefore
considered a targeted therapy.
Currently, there is no direct verification of the dose rate of a packed plaque
before its surgical insertion. The minimal quality assurance (QA) testing of this
treatment modality is most likely due to the relatively low number of patients re1

ceiving the treatment annually, the technical difficulty of measuring a packed plaque
prior to surgical insertion and its dependence on the availability of both brachytherapy sources and surgical theatre. The current practice is to measure the activity
of the seeds as they are packed, according to the treatment plan. This, however,
allows for the possibility of seed arrangement errors as there are no visual indicators
of a seed’s activity, and as such, the physicist must rely on calibrated activity measurements. The efficacy of the treatment planning system (TPS) at planning the
treatment must also be verified. Previous studies have legitimised silicon detectors
and a spectroscopy system for prostate brachytherapy using Iodine-125 brachytherapy seeds [5].
The first generation spectroscopic dosimetry system utilised a measurement
probe, mounted with a silicon diode as the detector element [6]. This probe was
found to be unsuitable for eye plaque brachytherapy dosimetry due to its angular
dependence, resulting in varied detector signal as a function of the incident angle
of primary photons. Due to the concave shape, primary photons are incident on
the detector from a large range of angles. In addition, an adjustment factor could
not be applied to account for this angular dependence as depth dose measurements
were conducted along the central axis of the plaque, resulting in the solid angle of
primary photons changing at each depth.
The aim of this thesis is to assess the capability of the previous system to be
repurposed and customised for the dosimetry of eye plaque brachytherapy.
A number of objectives have been developed in order to achieve a positive outcome:
• Develop a new spectroscopic dosimetry probe with improved angular dependence characteristics and a shallower depth of measurement for pre-treatment
dose verification and quality assurance of I-125 eye plaque brachytherapy
• Verify this design using Geant4 simulations
• Design a custom eye plaque phantom allowing for ideal dosimetric conditions,
2

while maintaining the sterility necessary for implantation of the plaque into
the patient
• Incorporate the phantom for use in the collection of automated depth dose
profiles

3

Chapter 2
Literature Review
2.1

The Eye

The eye is a complex, sensory organ responsible for vision. Vision is the dominant
sense in humans, accounting for approximately 70% of sensory receptors in the
brain [1], therefore any damage or illness related to the eye will significantly impact
quality of life. The adult eye is approximately spherical as depicted in Figure 2.1,
averaging at 24 mm in diameter with a function is to focus environmental light onto
photoreceptors found in its posterior through refraction.

Figure 2.1: Diagram of the eye showing, in particular, the anatomy of the uvea.
Adapted from [1]

4

Due to the eyes being situated in the bony orbits of the skull [7], only approximately
one sixth of the eye’s surface is externally visible with the remainder being enclosed
within the orbit and surrounded by protective fat deposits and extra-ocular muscles.
Within this anatomical region there are many important accessory structures of the
eye that are required for its protection and maintenance, such as the conjunctiva
and lacrimal glands. This area also contains very sensitive anatomy, such as the
optic nerve and cornea, wherein damage to these areas could result in vision loss.
Within the layers of the eye is the uvea [1] [7]. The uvea refers to the middle
of the eye and contains the iris, the ciliary body and the choroid. The choroid is
very vascular as it facilitates the blood and nutrient supply to the ciliary body,
the iris and to outer layers of the eye through a large number of densely packed
blood vessels. The choroid is also very rich in melanin to reduce the reflection and
scattering of light within the eye via the absorption of the stray photons, which
would otherwise degrade and contort vision.

2.1.1

Ocular Melanoma

Intraocular melanomas are malignancies of the melanocytes located within the eye
[2]. There are approximately 0.1 to 2.3 cases per 100 000 worldwide per year [3],
with 85% of these cases occurring in Caucasian individuals. Ocular melanomas have
relatively high mortality rates that increase along with the size of the tumour, as
shown in Table 2.1.
Table 2.1: 5 Year Mortality Rates of Ocular Melanoma [8]

Classification

Tumour
Size

Mortality
Rate

Small

<3 mm

16%

Medium

3 - 8 mm

32%

Large

>8 mm

53%

The poor survival rates of large masses in particular, indicate the importance of
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timely diagnosis and effective treatment [8]. Melanoma of the uveal layer is likely to
form metastasis disseminated through the blood stream to the liver and other organs
[9]. Due to the complex structure of the eye and its many anatomic features, there
are a large variety of cancers that can occur. The most common of these is choroid
melanoma, making up 90% of cases. Due to the choroid being highly vascular, a
relatively large amount of blood passes though it allowing for any diseased cells
from that area to travel throughout the body easily, increasing the risk of spreading
haematogenous metastasis to distant sites.

2.1.2

Treatment

Historically, these melanomas have been treated via surgery, by removing the eye
(enucleation) or through the removal of the mass through local resection [10]. The
full or partial removal of the eye not only results in the patient being effected from
a physiological loss of vision, but evidence suggests that a patient may experience
psychological side effects, leading to conditions such as depression [11] [12].
Alternative treatments of ocular malignancies include treatment using radiation
therapy that can be delivered via external beam therapies and brachytherapy [13].
External beam radiation in Australia primarily uses high energy photons targeted
onto the area of interest, however due to the delivery method of this radiation, areas in close proximity to the target can be exposed to high dose levels through the
processes of scattering. Internationally, proton beams have been used to successfully treat cancer and are advantageous due to their localised energy deposition,
commonly described by the Bragg peak [14]. However, there is no such treatment
available in Australia as it is considered to be too expensive in contrast to other
treatments.
More commonly, eye cancers are treated via low dose rate (LDR) brachytherapy
where small radioactive sources are used to irradiate the target area with low energy
photons over a long period of time [8]. There has been no observed difference in
survival rates between enucleation and brachytherapy [15], which strengthens the
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use of brachytherapy as a treatment modality due to the possibility of maintaining
sight and the sparing of the eye itself.

2.2

Brachytherapy

Brachytherapy involves the use of low energy radioactive sources placed adjacent to
or within the treatment volume [16]. These sources are sealed within an encapsulating material which prevents any chemical interaction or loss of the radioactive
material, and also acts to shield against any charged particles emitted from the
source [17]. The casing should not react with the surrounding the biological tissue and be of sufficiently high atomic number so that it can be easily identified in
images.
Generally, brachytherapy is conducted in two different forms. High dose rate
(HDR) brachytherapy involves sources that have a high activity and are only inserted
in the body temporarily. Interstitial catheters are inserted through, or alongside the
target volume. An external machine or afterloader guide the HDR source until it
reaches the desired destination known as a dwell position. It is held in that position
for a pre-determined time (dwell time), usually of the order of seconds, then moved
by the afterloader into the next position [18]. A large dose can be delivered to
the target tissue in a short amount of time without significant entrance or exit
doses, as seen in external beam radiotherapy. The high dose delivered is particularly
advantageous when applied to tissues with a low α/β ratio, as they are most likely
to benefit from dose escalation [19]. In low dose rate (LDR) brachytherapy the
sources are most commonly radioactive seeds with a low activity that are left within
the body for long periods of time. In some cases, seeds remain in the patient for
just a few days to a week while other patients undergo permanent implantation.
The number of seeds used varies with each treatment with larger volumes such as
the prostate requiring more seeds than those necessary for eye plaques. Over this
time, the radiation emitted by these sources are incident on the surrounding tissue,
effectively treating the target area.
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The advantages of using this radiological treatment modality include achieving
a non-uniform distribution of radiation emission, steep dose gradients over small
distances that can be established due to the very low energy sources, targeted irradiation of the treatment volume, and sparing the surrounding normal tissue [18].
This improves the tumour control probability and decreases the normal tissue complication probability.

2.2.1

ROPES Eye Plaque

LDR brachytherapy is employed in the treatment of ocular melanomas through the
use of an eye plaque. Although many exist, the most common eye plaques used in
brachytherapy are the Collaborative Ocular Melanoma Study (COMS) plaque and
the Radiation and Oncology Physics and Engineering Services, Australia (ROPES)
plaque, the latter of which is used and widely available in Australia. The AAPM
TG-43 U1 protocol, which will be outlined below and is the current standard in
brachytherapy dosimetry formalism [20] can be used to performed dosimetry of
either plaque. Studies into the COMS protocol has found that the survival rates
for patients with small- and medium-sized tumours are equivalent when treat with
COMS brachytherapy and enucleation [21]. The ROPES plaque can be seen in
Figures 2.2 and 2.4.
The 15 mm ROPES eye plaque is composed of an acrylic mould that holds a
total of 10 radioactive seeds in place and a stainless steel cap or applicator. The
mould also completes a secondary function placing the radioactive sources 1 mm
from the surface of the eye. The applicator both encapsulates the seeds and shields
the tissue around the orbit including the brain from radiation. Stainless steel is a
convenient material to use as it does not react or oxidise within the body and has a
relatively large effective atomic number, increasing its ability to attenuate photons
and therefore act as a shield for surrounding tissue. The applicator is shaped as a
spherical shell. Specially shaped plaques are required in the treatment of tumours
located close to the optic nerve [22]. This allows for the treatment of tumours of
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Figure 2.2: Diagram the 15 mm ROPES Eye Plaque. Adapted from [22]

varying sizes; delivering the prescribed dose to the target area, whilst ensuring the
smallest possible dose to the surrounding healthy tissue. There are several different
ROPES eye plaque designs, including an 11, a 15, an 18 and a 20 mm diameter
model, all of which are available with either a flanged or simple eyelets used to
stitch the plaque in place.
The applicator and mould are then attached to the sclera and left for approximately 3-7 days before being removed [23]. Generally, a dose of 80-100 Gy is
recommended to be delivered to the apex of the tumour at a rate of approximately
0.60 - 1.05 Gy/hr [24]. The American Brachytherapy Society has found that dose
rates lower than those recommended were associated with inferior tumour control.

2.2.2

Iodine-125 Brachytherapy Source

There are a number of radioactive sources used in the treatment of cancer via
brachytherapy. HDR brachytherapy uses high activity sources that generally emit
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photons with much higher energies when compared to LDR sources, with energies
of the order of a few hundred keV [25]. Due to the high activity and greater photon
mean-free path of HDR sources, they have the potential to cause significant damage
to healthy tissue and can only be used for very short intervals before being removed.

Figure 2.3: The Oncura OncoSeed model 6711 schematic with dimensions.
Adapted from [26]

The seed commonly used in eye plaque brachytherapy in Australia is the Oncura
OncoSeed model 6711, which contains the radioactive element Iodine-125. It consists
of a cylindrical sliver core; 3 mm long and a diameter of 0.5 mm, which is coated
with radioactive Iodine and encapsulated by a titanium shell, as shown in Figure
2.3. This shell is 4.5 mm long and has a diameter of 0.8 mm. It is important to note
that the shell does not have uniform thickness, contributing to the anisotropy of the
emitted radiation. The shell is 0.5 mm thick at the ends and 0.06 mm thick along
the sides. There exists a small cavity between the silver rod and titanium capsule
which does permit the source to have a small amount of moment within the seed
[26].
The primary energy emission of I-125 is approximately 27 keV with a half-life
of 59 days [12] however the 6711 seeds emit a variety of wavelengths both from the
I-125 decay scheme and from silver core characteristic X-rays, as shown in Table 2.2.
The table shows the relative frequency of the gamma ray energies emitted per 100
decays of the I-125 or the frequencies of the characteristic X-rays per 100 vacancies
of that electron shell. This occurs when an I-125 photon is incident on the core
and is absorbed via the photoelectric effect. A subsequent electron cascade with the
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Table 2.2: Oncoseed 6711 I-125 photon spectra

Photon

Mean Energy
(keV)

Intensity per 100
decays/vacancies

Ag Kα1

22.16

45.6

Ag Kβ3

24.94

7.5

X Kα2

27.20

40.6

X Kα1

27.47

75.7

X Kβ3

30.94

6.8

γ

35.49

6.7

affected silver atom causes an x-ray to be emitted contributing to the overall dose
delivered by the 6711 seed. These main emissions include 22 keV, 25 keV, 27 keV,
31 keV and 35 keV photons [5].

2.3

Importance of Quality Assurance

Quality assurance is of paramount importance in radiotherapy [27]. It ensures that
the prescribed dose is delivered to the target volume with high levels of accuracy and
reliability as well as minimising the radiation exposure of healthy tissue, thereby
making the modality safe and effective [28]. Although there are both planning
and dose calculation systems utilised in clinical sites to ensure the required dose
is delivered, the software included in these systems is limited by the algorithms
included and the time it takes to calculate the plan. Therefore, quality assurance
acts as an external verification. Another important facet of QA procedures is to
certify that the various components and equipment used during a treatment are
functioning as expected and to accepted standards.
Eye plaque brachytherapy is a complex treatment modality that requires rigorous QA measures. The American Association of Physicists in Medicine (AAPM)
formed Task Group No. 129 (TG-129) as a review of eye plaque radiotherapy
[29], specifically treatments utilising COMS (Collaborative Ocular Melanoma Study)
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plaques. The review found that for treatments using these COMS plaques, loaded
with I-125 seeds and with a standard prescription of 85 Gy at a 5 mm depth, the
dose delivered was 75 Gy. This is a discrepancy of approximately 12%. The AAPM
suggest that further scrutiny be applied to the Monte Carlo algorithms used to
calculate the dose delivered and that this is best achieved by ’further dosimetric
evaluations’. These algorithms assumed that the seeds would be contained in a homogeneous environment rather than a realistic heterogeneous one. The findings of
the task group are significant enough to prompt the development and implementation of a new and thorough QA protocol based on externally measuring the dose at
the prescription point prior to plaque insertion. Other studies specifically recommend that QA procedures help to improve positional accuracy of dose deposition
and reduce the chance of incorrect placement of seeds within the plaque [30].

Figure 2.4: Picture of a 15 mm ROPES eye plaque, acrylic insert and I-125
seeds

Standard Quality Assurance procedures for eye plaque brachytherapy treatment
at Prince of Wales (POW) hospital, Randwick, follow TG-129 guidelines [29]. These
are modified for a ROPES plaque as the AAPM only considered COMS plaques in
their report. Plaque Simulator 5

TM

, Eye Physics, is employed as the treatment

planning system (TPS), which uses the activities of available seed batches to formulate a plan to best carry out the prescription. An independent check of the plan is
performed using the brachytherapy module in RADCALC T M LSI Inc., modified for
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eye plaques [31]. The discrepancy between the two plans should be no more than ±
2% [4].
There are only two batches of seeds available at any one time for use in eye plaque
brachytherapy at POW, the new and the old. This reduces both the confusion and
probability for mistake when determining which batch a seed comes from, as over
time the sources will decay making it easy to discern between the batches.
The plan must be checked to ensure the planned dose rate is between 60 −
105 cGy/hr to the prescription point as well as to see if it has been formulated
for the correct eye. If either of these conditions fail, the treatment must be replanned. Once a plan has been accepted, the pre-insertion quality assurance is
conducted. The activity of the seeds in each batch is measured individually by
using a well chamber [29] and the mean activity determined. The measured mean
activity of a batch should lie within ± 3% of the activity presented by the seed
manufacturers certificate. The mean batch activity and the comparison calculation
are then independently checked by a second physicist. The plaque and seeds are
placed in the autoclave for sterilisation, while the temperature and pressure of the
process monitored to ensure they are within the appropriate limits. The plaque is
then packed under direct supervision of a second physicist, to ensure placement of
seeds follows the plan outlined by the TPS.
Currently, there is no check to directly measure the dose rate of the loaded
plaque to quantify how well it conforms to the TPS plan and if there have been
any errors in the placement of the seeds missed by both physicists [4]. As the
seeds themselves have no discernible features and the plaque contains no position
identifiers, there is a significant probability of an error occurring in the form of a
misplaced seed. Current eye plaque brachytherapy QA is not robust, which could
allow the case presented by TG-129 above, where delivery of a dose 12% under
the prescribed to occur. This could ultimately lead to local control failure. If the
physicist was unsure of the plan, investigations using radiochromic film could be
conducted, however these tests require a relatively long time to read-out results,
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which is not conducive to the clinical environment. The implementation of a fast
read-out, small volume, spectroscopic dosimeter, measuring the depth dose along
the central axis of the probe, would further ensure the conformity of the plaque to
the plan, but also determine if the plan directly delivers the dose rate indicated.

2.4

TG-43 U1 Protocol

Brachytherapy is a diverse branch of radiotherapy. Many different sources, seed
designs and placement techniques can be employed in a treatment regimen. As
stated previously, enucleation and brachytherapy have equivalent survival rates in
the treatment of ocular cancers but only brachytherapy allows a possibility of visual preservation [21]. The only way that this outcome is achievable is through the
correct execution of the treatment plan, such that the radiation interacts with the
target tissue and spares the sensitive sight structures, such as the optic nerve. The
AAPM formed Task Group No. 43 (TG-43) in 1995 to introduce standards and
protocols into the dosimetry of brachytherapy and to address issues found in dated
dose calculation formalism that did not take several important factors into account
[32]. The update, TG-43 U1, was released in 2004 by the AAPM due to the dramatic increase in brachytherapy cases both with interstitial and permanent source
implantation since the original report [33]. The data used in the protocol are derived from a combination of experimental and MC simulations. Thus, the formalism
involves a number of assumptions. One such assumption is that the dose rate can
be determined in an infinite water phantom, and thus cannot take heterogeneities
into account, such as in the case of eye plaque brachytherapy. While not taking the
wider environment into account, this allows for the TG-43 protocol to be pertinent
in the majority of clinical brachytherapy applications.
The following is the TG-43 U1, 2-dimensional formula for the dose rate of an
individual seed:
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Ḋ(r, θ) = SK .Λ.

GL (r, θ)
.gL (r).F (r, θ)
GL (r0 , θ0 )

(2.1)

where r is the distance between the centre of the source and the point of interest
P(r,θ) in centimetres as shown in Figure 2.5, θ is the polar angle subtended between
P(r,θ) and the central axis, r0 and θ0 are standard measures at 1 cm and 90◦ from the
centre of the source and the central axis respectively. SK is the air kerma strength,
Λ is the dose rate constant, GL (r) is to the geometry function at P(r,θ), gL (r) is the
radial dose function of the line source and F(r,θ) is the 2D anisotropy function.
This formula is built around the assumption that each seed is a cylindrical source
can be approximated by a line. Apart from the seed design and composition, the
dose rate is primarily determined by the distance the seed is from the point of interest and the angle formed between them.

Air-Kerma Strength:
Air-kerma strength refers to the air-kerma rate of radiation in a vacuum, where
kerma is the expected energy released per point per unit mass by incident radiation
[34]. SK has units of cGy.cm2 .h−1 and its formula is as follows:
SK = Kδ (d)d2

(2.2)

Where Kδ (d) is the air-kerma rate at a distance d, along the transverse plane of
the seed. The point of measurement is sufficiently far from the seed such that the
source can be treated as a single point and that SK is independent of d, typically 1
metre. Kδ (d) also contains a low energy threshold denoted by δ, which is usually 5
keV. This is due to the low energy X-rays originating in the metallic capsules of the
source having the potential to increase the air-kerma dose rate without contributing
to the dose over distances greater than 0.1cm.
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Dose Rate Constant
The dose rate constant Λ is the ratio of the dose rate at a reference position
in a medium (liquid water is recommended) to air-kerma strength. This reference
position is designated as P (r0 , θ0 ). The formula for the dose rate constant in water
is:

Λ=

Ḋ(r0 , θ0 )
SK

(2.3)

This is an absolute quantity with the units cm−2 [32]. This constant is dependent on the source material, geometry and composition used in the treatment, which
can affect the energy spectrum of the radiation emitted. This variable is important
for calibration purposes of any detectors used.

Geometry Function
The geometry function is an approximation based on the characteristics of the
source, specifically the distribution of radioactivity within the seed, while also improving accuracy by acting as an inverse square correction. When using the twodimensional model the geometry function is as follows:

GL (r, θ) =






β

, if θ =
6 0◦
Lr
sin
θ


 (r2 − L2 )−1 , if θ = 0◦
4

Where β is the angle made up of the lines formed between both the edges of the
line source to the point of interest as shown in the following diagram:
The active length L used in this calculation can be substituted with Lef f depending on the structure of radioactivity within the seed. An example of the different
structures can be seen in Figure 2.6. L can be used in the case shown in Figure 2.5,
where the radioactive source is a uniform cylinder. Lef f is required in seeds that
contain uniformly distributed sources and is described by:
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Figure 2.5: Diagram of TG-43U1 formalism. Adapted from [32]

Lef f = ∆S × N

(2.4)

where N is the number of sources within the seed and ∆S is the spacing between
each source from their centres.

Radial Dose Function
The radial dose function attempts to account for the sharp gradients on the
transverse plane due to attenuation and scattering. Together with the geometry
function they provide realistic corrections, improving the accuracy of the calculated
dose rate. The radial dose function is defined as:

gL (r) =

Ḋ(r, θ0 ) GX (r0 , θ0 )
Ḋ(r0 , θ0 ) GX (r, θ0 )

(2.5)

Where the subscript is denoted by an L when considering the two-dimensional linesource case or a P for a point-source. This quantity can be found in look-up tables
included in the TG-43 U1.
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Figure 2.6: Diagram of a) Oncura 6711 OncoSeed, b) Oncura 6702 I-125
brachytherapy seed. Because of the individual internal structures 6711 and 6702
would use L and Lef f respectively in the calculation of the geometry function.
Adapted from [26]

2D Anisotropy Function
There is a significant inhomogeneity around brachytherapy seeds due to the absorption and scattering of photons through the encapsulating material. In addition,
the radio-opaque marker within the seeds themselves, can absorb photons, further
contributing to anisotropy. The 2D anisotropy function describes this variation in
dose and is defined as:

F (r, θ) =

Ḋ(r, θ) GL (r, θ0 )
Ḋ(r, θ0 ) GL (r, θ)

(2.6)

To maintain consistency, the L used in GL (r, θ) is the same as was used in the geometry function, either the active length L or effective length Lef f . A failure to do
this would result in errors, particularly in measurements very close to the seed.

Some of the oversights of TG-43 U1 include that it does not consider variables
that may affect the actual dose rate apart from those related to the structure and
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orientation of the seed. Large portions of the body are made up of tissue that is
relatively dense when compared to water, such as bone. Equivalent dose calculations must be performed to supplement TG-43 U1 in order to accurately depict the
dose delivered to non-water substances and in areas of tissue inhomogeneity. Extra
consideration must also be made to the applicators used to mount brachytherapy
seeds and their effect on the dose delivered as the presence of an applicator can
change the value of the anisotropy function [35].

2.5

Photons Interactions

Photons can interact with matter in many ways, however the likelihood of each
of these interaction modes are primarily dependent on the energy of the photon
and the medium it traverses [36]. It the interaction of a photon with matter that
causes damage to tissue; through the ionisation of electrons and nuclear processes.
Photons are electrically neutral and therefore do not continuously lose energy in
matter as charged particles do, but instead have a probability of interaction following
a statistical model. Although each individual radiation event occurs randomly, the
average rate at which these events occur over a larger time period can be reasonably
predicted and thus described with Poisson statistics [37].

2.5.1

Elastic Scattering

When an incident photon has a sufficiently low energy it can undergo elastic scattering, with only a negligible loss of energy due to the conservation of momentum
[34]. Thomson scattering consists of the incident photon interacting with a free
electron. This electron then undergoes classic oscillation [5]. This oscillation results
in the emission of a photon in the direction as determined by the electron’s electric
orientation [37].
Rayleigh scattering, like Thomson scattering, is a process where the incident
photon does not transfer its energy to the medium it interacts with. When an

19

incident photon of sufficiently large wavelength interacts with a whole atom it can
cause all of the electrons bound to that nucleus to oscillate in phase, leading to the
emission of a photon with the same frequency as that of the incident photon but
in a new direction [5], as shown in Figure 2.7. Photon interactions with an entire
atom are known as coherent. Rayleigh scattering has a relatively low probability of
occurring when considering the short wavelengths used in a clinical environment.

Figure 2.7: The kinematics of Rayleigh Scattering where a) shows the photon
incident on an atom and b) the subsequent vibration of the atom and re-emission
of the photon with no energy loss

Elastic scattering is of limited significance in radiation treatments or in diagnostic radiology as no energy is absorbed by the medium, nor is the energy transformed
into electronic motion, which are the main two vehicles for cell death in radiotherapy [38]. However, it does influence the trajectory of radiation and therefore the
absorption cross-section of the medium.

2.5.2

Energy Deposition Mechanisms

There are several mechanisms by which photons lose their energy via their interaction with matter. Considering the relatively low energy photons emitted from
LDR Brachytherapy sources, only the relevant interactions will be addressed. These
interactions include the Photoelectric effect and Compton Scattering, with their
kinematics shown in Figures 2.8 and 2.9 respectively.
The photoelectric effect is an interaction characterised by an incident photon
ejecting an inner shell electron from an atom. The incident photons energy is fully
20

Figure 2.8: The kinematics of the Photoelectric effect on an atom with electron
shells shown. Adapted from [39]
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absorbed by the electron giving it sufficient kinetic energy to overcome the binding
energy of that electron shell and is ejected from the atom [34]. The kinetic energy
gained by the electron is independent of its scattering angle and can be described
by the following equation:
T = hν − Eb

(2.7)

where hν is the energy of the incident photon, Eb is the binding energy of the
electron and T is the kinetic energy of the ejected electron. This effect occurs most
readily when then incident photon has an energy the same or just higher than the
binding energy of an electron shell. The K and L shells are the first and second
largest contributors to photoelectric absorption, respectively.
The photoelectric effect results in a positive ion whose electrons are not in a
stable configuration due to the presence of an incomplete inner shell. This can cause
an electron cascade where electrons from higher energy states that are less tightly
bound and further away from the nucleus, transition down to occupy the newly
vacant energy levels. The electrons require a smaller amount of energy in their new
positions than they did in their previous shell. The energy difference between the
two energy states is then released in the form of X-rays, which is characteristic to
both the element and shells effected, the result of which makes the atom become
stable once again.
Compton scattering describes the interaction of a photon with sufficient energy
and an unbound, stationary electron [34]. A transfer of a proportion of the incident
energy and momentum to the electron results in the scattering of both the photon
and electron at angles θ and φ respectively, relative to the photons original direction.
As a result of the conservation of energy and momentum, the product of the
interaction is the reduction in the photons energy and the motion of the electron.
The proportion of energy transferred from the photon, or the magnitude of the
photon frequency shift is determined by the initial photon energy and the angle
at which the photon is scattered by the particle, as shown through the following
equation [5]:
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Figure 2.9: The kinematics of Compton Scattering. Adapted from [34]

hν

hν 0 =

(2.8)
hν
1+

me c2

(1 − cosθ)

Where h is plank’s constant, ν is the photon’s initial frequency, ν’ is its final frequency, c is the speed of light, me is the mass of an electron and θ is the angle of
the scattered photon relative to its original direction.
The photons energy loss reaches a maximum when θ = 180◦ . Due to this upper
energy limit of scattered photons of a single energy, a feature known as a Compton
edge can be observed when organised into an energy spectrum. This feature is
characterised by a low energy plateau relative to a photopeak, where a photopeak
represents the events due to photoelectric absorption. The Compton edge location
is before a distinctive energy gap that is approximately the size of the maximum
energy loss of the photopeak energy due to Compton scattering. Thus, a proportion
of the photon’s energy being lost through this process, there is a significant potential
for particularly low energy photons to be scattered multiple times. This is significant
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in eye plaque brachytherapy where photons are generally under 100keV.

2.6

Electrons Interacting with Matter

Electrons, or beta particles, traverse through matter in ways different to massless,
electroneutral photons. They can collide with nuclei directly, are affected by the
Coulomb force and, like photons, have the ability to excite and ionise atoms [25].
The majority of electron interactions with matter are due to the Coulomb force,
which can be described in the following formula:

F =

Q1 Q2
4π0 r2

(2.9)

It can be seen from the above formula that the two charges act upon one another
and both the magnitude and the polarity of the charge determine the impact of the
force on the beta-particle. For the purposes of clinical treatments, and the related
energy range, only collisional and radiative interactions will be considered in the
following paragraphs.
Electrons undergo a multitude of interactions as they move through a material,
such that its behaviour can be best described through the probability of an interaction occurring. One way to predict the passage of the electron is to consider its
trajectory past a nucleus, relative to the radius of the electron cloud [25] [34]. When
b >> a as shown in Figure 2.10, beta particles can undergo ’soft’ collisions, or can
be scattered elastically by the atoms electric field. The elastic process can occur a
number of times, which can result in the particle travelling a relatively large distance
from where it originated. This effect is particularly significant at low energies [18].
When b = a, or b < a, the interaction generally results in collisional or radiative
process, respectively. The energy loss per unit length of an electron is described as
the stopping power, which is split into two terms; collisional and radiative as shown
in equation 2.10. Both of which are dependent on both the energy of the electron
and the density of the traversed material [18].
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These two interactions dominate at different energies within a material. Collisional interactions generally dominate at low energies, whereas radiative interactions
increase proportionally to the kinetic energy of an electron, and so are the dominant
interaction of high energy electrons. The following equation approximately expresses
the likelihood on each interaction taking place as a function of the atomic number
of the absorber medium and of the incident energy of the electron:
(−dE/dx)−
ZE
rad
− ≈
800
(−dE/dx)col

2.6.1

(2.11)

Collisional Interactions

Electrons, being massive particles, have the potential to physically collide with surrounding particles and through a single collision, can potentially lose a large portion
of their energy. Generally, collisions occur when b >> a or b = a, as shown in Figure
2.10. The transfer of energy from the incident electron to an orbital electron in a
collision can result in ionisation or excitation, both of which are states that lead to
the emission of characteristic X-rays and/or Auger electrons. Ionisation is where an
outer shell electron is permanently ejected from the cloud resulting in an atom with
a net positive charge, whereas excitation is when an orbital electron gains enough
energy to exist in a more energetic orbit only temporarily. The majority of electron
collisional interactions result in a small net loss of energy, however, when they do
transfer a large portion of their energy to an orbital electron, this electron is known
as a δ-electron, which can then go on to have collisions with other orbital electrons
[18] [36] [34].

25

Figure 2.10: Diagram of electron collision interactions. a is the atomic radius and b is the distance of the trajectory of the electron to the atom nucleus.
Adapted from [34]

2.6.2

Radiative Interactions

Bremsstrahlung, or braking radiation, is the phenomenon where an electron is deflected by the Coulomb force due to the electric field of a positive nucleus, mainly
occurring when b <a, as seen in Figure 2.10 [36] [25]. As the electron traverses the
strong electric field of the positive nucleus, it undergoes both a change in direction
and a reduction in kinetic energy, as shown in Figure 2.11. Any loss in kinetic energy is directly translated into the emission of electromagnetic rays following local
conservation of energy, whose direction is dictated by conservation of momentum.
As there is a larger force exerted on the electron coming within a smaller distance,
the angle at which it is deflected is also large.
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Figure 2.11: Diagram of Bremsstrahlung production. Adapted from [34]

2.7

Radiation Detectors

Since the production of high purity silicon became commercially viable, radiation
detectors have been fabricated based on semiconductor technology [37]. There are a
number of properties semiconductors possess that make them suitable for the detection of radiation. They (silicon) have a very small ionisation energy of 3.62 keV [37],
which is the amount of energy required to produce an electron-hole pair from within
the crystalline lattice [40]. In comparison, a typical gas-filled radiation detector has
an ionization energy of approximately 30eV. Because the number of charge carriers
produced per energy deposition is much larger, semiconductor detectors have better
signal to noise ratios when compared to gas-filled chambers. They also have a relatively high density (2.33g/cm3 ) and atomic number (14), which contribute to a large
energy loss per unit length for an incident particle travelling through the medium.
Silicon detectors can be made for a relatively low cost and are highly reproducible from batch to batch. They operate well at room temperature, where other
semiconductors, such as germanium, require low operating temperatures to reduce
thermal current. Small sensitive volumes are achievable due to a high charge collection efficiency which in turn results in excellent spatial resolution. In addition to
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desirable material properties, silicon detectors are extremely practical requiring low
operating voltages and are able to output data in real time.
Conversely, there are some considerations that must be made when using silicon
semi-conductors in radiation detection. The pathway of radiation energy deposition
has the potential to damage the silicon substrate and the silicon oxide interface [41].
Thus, increased exposure to radiation can degrade the detector’s response. Incident
radiation can displace atoms within the crystal lattice, resulting in mobile holes
within the substrate binding together to form a trapping site. The result of which
is increased noise, decreased sensitivity, a reduction in the carrier mobility, charge
collection efficiency and the detectors lifetime [42][37].
Furthermore, the application of semiconductor devices to clinical dosimetry
present some complications associated with their material composition. Much of
clinical dosimetry measures the energy deposited in water, which acts as an analogue to tissue. At low energies, the dose to silicon is enhanced relative to the dose
in water, due to a high photoelectric cross-section [43]. The distribution of the attenuation coefficient of silicon relative to water is represented in Fig. 2.12. This
makes dosimetry in that energy region somewhat erroneous.

2.7.1

Diode detectors

Within a homogenous crystal lattice, semiconductors have a well-defined electron
band structure; a conduction band, a valence band and a forbidden energy gap where
allowed energy states for electrons do not exist [40]. Conductors have no energy gap,
while semiconductors have a relatively small energy gap compared to insulators [36].
Impurities can be introduced into the lattice such that the substrate may have an
extra charger carrier. If the impurity added is a group V element, it is defined as
a donor as it introduces an extra electron, forming an n-type semiconductor. If
the impurity is a group III element, it is defined as an acceptor as is introduces
a positive hole, forming a p-type semiconductor. The introduction of these charge
carriers also alters the energy bands within the lattice, allowing energy states within
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Figure 2.12: Mass absorption coefficient of water and silicon, showing the low
energy discrepancies between the two (data from [43])

Figure 2.13: Diagram outlining the band structure of dope and un-doped semiconductor material. The pink and blue bands represent the conduction and valence bands respectively while the black circles are electrons and the white, holes
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the forbidden gap [44], pictured in Figure 2.13.
When two oppositely doped regions are in direct contact, there is a build-up
of charge close to the interface on either side. This is due to the diffusion or drift
of both donors and acceptors across the junction, leading to the establishment of
an electrical potential across the junction [44]. In this region, the concentration of
charge carriers is reduced due to occupied acceptor and immobilised donor sites,
otherwise known as the depletion region.
Radiation detectors are generally employed using a reverse bias configuration,
where an external potential difference is applied across the sensitive volume. Under
reverse bias conditions, only electrons from the p+ region and holes from n-, also
known as minority carriers, are attracted across the junction [34]. This serves several
purposes including; lowering the leakage current and diode capacitance, forcing the
current to travel in only one direction and increasing the volume of the depletion
layer [45]. The concentration of charge carriers within the depletion region decreases
due to the flow of only the minority carriers, resulting in a reduced leakage current.
Reverse biasing also serves to increase the potential difference across the junction
resulting in an extension of the depletion region [37]. This can be seen in Figure 2.14,
which outlines the effects of reverse-biasing a semiconductor. Following this increase
in potential difference comes the extension of the depletion region [37]. According
to Poissons equation;

∇2 ϕ = −

ρ


(2.12)

where ϕ is the electrical potential, ρ is the net charge density and  is the dielectric
constant. As the potential increases, it then follows that space charge must also
increase. This increases the width of the depletion region and therefore the sensitive
volume of the detector.
When radiation of sufficient energy is incident on this area, electron-hole pairs
are produced that have the potential to travel relatively large distances before recombining. This is achieved by the electrical potential that forms over the junction
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Figure 2.14: Diagram outlining the depletion volume, electric field, electrical
potential and energy bands of the junction between the n-type and p-type regions of a radiation detector with a) no external voltage applied and b) under a
reverse bias configuration. Black and white circles represent electrons and hole
respectively. (adapted from [44] and [37])
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due to the net charge of electrons in the p-type and holes in the n-type region. It
is the current formed by the motion of these charges that allows the detection of a
radiation-matter interaction.

2.8

Spectroscopic Dosimetry

Spectroscopic dosimetry is defined as the determination of the dose rate at the
point of a measurement based on the number of events within the photo-peaks
of a measured spectrum [46]. The energy of a source is important in non-tissue
equivalent detectors, such as silicon diodes [37]. The absorbed dose in a detector
may have an inherent energy dependence relative to the absorbed dose to water, and
therefore the read reading taken may have no clinical significance. If the radiation
energy can be determined at each point along its trajectory, then the absorbed
dose to water deposited along that track can be more accurately determined, using
whatever material is available [34].
When considering the absorbed dose in an LDR brachytherapy regime, the effect of a source spectra is often overlooked. Currently, there are only very limited
numbers of publications referring to a spectroscopic analysis of LDR brachytherapy
[6][47]. However, there are a number of advantages to approaching dosimetry from
a spectroscopic perspective.
Firstly, the majority of photon-emitting radioactive sources are not mono-energetic
and treating it as such can lead to an incorrect estimation of the dose. Analysing
each of the major photo-peaks intensity and energy to determine its relative contribution to the dose leads to an accurate net dose measurement. When conducting
depth dose measurements, each photo-peak will have a reduction in size due to
attenuation in the medium. This is due to the following relationship;

I = I0 e−µx ; µ ∝ 1/E 3

(2.13)

where the attenuation coefficient of a photon, µ, is inversely proportional to the cube
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of the photon energy. Because of this relationship, each of the photo-peaks will be
attenuated at different rates relative to one another. When performing depth dose
measurements, the lower energy photons will be attenuated the most, resulting in
the largest relative decrease in photo-peak intensity.

Figure 2.15: Spectrum of an OncoSeed 6711 brachytherapy source as measured
by a silicon detector and spectroscopic set-up

When considering the spectra collected from a source, such as in Figure 2.15,
there is information other than the photo-peak height present in the data that
can be investigated. The presence of any electronic noise in the detector system
would be evident in a spectrum as low-energy events. This has the potential to
cause inaccuracies in the overall dose measurement due to the sheer number of these
counts that can be accumulated at a very high rate. There are also a large number of
Compton scattering events contributing to low energy counts, particularly in the low
energy radioisotopes prevalent in LDR brachytherapy. For example, approximately
40% of photons emitted from an I-125 source undergo Compton scattering [43] and
all of the recorded events associated with this interaction have a very low energy. In
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order to consider only the clinically relevant events in determining the actual dose
deposited these low energy counts can be ignored by setting an energy or lower level
threshold to remove these low energy events from the spectrum.
Converting electronic signals to energy deposited requires a number of steps.
Initially, a preamplifier system with a feedback capacitor collects the charge output
by the detector. As the charge increases, the potential difference of the capacitor
also increases sharply [37]. This rise in voltage is proportional to the total charge
collected and in turn to the energy deposited by the radiation event. Over time,
the signal exponentially decreases to pre-event levels. This decay is imperative to
avoid saturation of signal due to the event signals piling on top of one another. The
amplifier then shapes the signal into a form that can be easily read by a multichannel analyser (MCA). Pulse shaping can occur using differential and integral
discriminator circuits [37]. The former produces an output signal that essentially
acts as a high-pass filter, where low frequency signals are- and high frequency pulses
are not attenuated. This acts to remove the long decay tail of the pre-amp signal
while keeping the rise of the pulse intact. The integral circuit acts as a low pass filter;
attenuating high frequency signals, while allowing low frequencies to pass through
unchanged. This integration would smooth a pulse with a steep gradient into having
a more gradual rise. However, this will only take place if the linear input pulse, from
the preamplifier, has an amplitude larger than a pre-defined discriminator level. The
output signal takes the shape of a Gaussian curve, which is an average of the signal
pulse produce earlier. Thus, the discriminator allows the system a certain amount
of functional flexibility, whereby noise can be eliminated or certain signals can be
recorded. The MCA can then bin the Gaussian signal according to pulse height,
and record them as counts and display that information as a spectrum.
Running the system in this manner limits the ability of the device to operate
under a high count-rate environment due to shaping time. Count pile-up is where
successive pulses ’pile up’, which occurs both as outlined above due to a signal pulse
occurring before the previous one has decayed and when more than one pulse is
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Figure 2.16: Diagram showing the effect of clipping. Solid line shows the
’clipped’ amplitude of the signal, dotted line shows the desired signal

processed within one integration time [37]. The pulse height of this event is added
to the height of the previous signal, resulting in a signal that is not representative
of the energy deposited by the photons. Another consequence of a high count-rate
and count pile-up is clipping, where pile-up pulses saturate the amplifier, as shown
in Figure 2.16. When clipping occurs, the pulse height corresponds to the maximum
output voltage of the amplifier and results in events binned in the highest channel
of the MCA spectrum.

2.9

Monte Carlo Simulations

Computer modelling in physics is a rapidly growing field. These systems are a
means of testing hypotheses without costly equipment and technology. It can also
serve to set theoretical benchmarks and standards in ideal conditions. It has the
ability to track billions of individual particles’ passage through matter from high
energy ions to auger electrons. The basics of simulating radiation physics is rooted
in randomness and probability, and such are named ’Monte Carlo’ simulations, after
the region home to a large casino in Monaco.
The Monte Carlo method is a technique of computing algorithms through prob35

abilistic analysis [48]. Monte Carlo simulations can be used to track the trajectory
of individual particles [49]. Radiation can be modelled by randomly selecting the
physical interactions it undergoes, as well as any secondaries produced. The probability of certain event occurring is determined by the radiation type and energy as
well as characteristics of the medium through which it travels. By simulating the
tracks of a very large number of particles, the quantity of interest (often absorbed
dose in media) can be calculated. Practically, the Monte Carlo method is employed
in simulating radiation transport in three steps [50].
1. Firstly, an input of information describing the model must be defined. This
includes defining the relevant characteristics of media included in the model,
such as water and silicon. Libraries of applicable radiological characteristics,
such as the probability of energy dependent interactions, attenuation coefficients and stopping power ratios, can then be referenced. The physical geometries of the simulation environment are constructed in three-dimensions,
where complex bodies are formed by adding and subtracting standard shapes
and are assigned a previously defined medium. Some of these volumes may be
assigned as scoring volumes, where the system records predefined dosimetric
data generated in that volume.
Once the geometry of the simulation environment has been demarcated, the
primary radiation must be defined. This includes the radiation-type, its energy, geometric position/source within the model, the initial direction of the
radiation and the number of primary particles generated. Finally, the features
of the simulation itself must be input. For radiation transport models this
includes, the radiological interactions to be considered and any relevant energy thresholds/cut-offs are input, while more generally, the random number
generator and its initial starting point is defined.
2. The simulation generates random primary particles and performs quantitative
analysis on them. This process includes determining the path length of an
individual primary particle due to predefined conditions. The probability of
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an interaction occurring is calculated based on the radiological characteristics
of the simulation. Then, the interactions a particle undergoes is determined
by the random number generator, whereby the interaction selected is from the
weighted probability model. This primary particle and any other generated as
it traverses a medium, are tracked until the energy of the particle is below the
cut-off threshold. Each interaction of an individual particle and the subsequent
energy transmission is tabulated throughout its trajectory.
3. The information tabulated from each individual particle is then summed to
produce an output. This output was determined by the set-up of the scoring
volume discussed above. This data can be organised in several ways, for example the energy deposited in a volume can be binned according the magnitude
of energy transferred in a single interaction to produce a spectrum.
Brachytherapy dosimetry has been traditionally based on calculations assuming
a homogeneous water phantom volume following TG-43 U1. Previous Brachytherapy
models using Monte Carlo have compared realistic heterogeneous mediums based on
CT datasets with TG-43 U1 calculations, limited by considering only homogenous,
water media. Theoretically, the influence of patient geometry and heterogeneities
is higher with low energy photons associated with brachytherapy, due to the high
proportion of photoelectric interactions.
Comparisons between the TG-43 U1 dosimetric calculations and Monte Carlo
models for breast Ir-192 plans have been conducted, utilising treatment planning
CTs to create a density map [51]. A density map was used along with a look-up
table to assign elemental composition to areas with specific electron densities. The
comparison revealed that TG- 43 U1 over-responded in areas with a low photon
energy and it was assessed as being unable to accurately handle scatter radiation.
While the over-response did not influence the dose calculation of the whole plan
(< 2%) deviation, local dose regions showed discrepancies from 5 - 30% as the
points moved further away from the implant. In particular, TG-43 U1 did not
represent the lung dose well and resulted in an overestimation of the dose proximally
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of approximately 10% and then an underestimation of the dose at points further
away from the sources in the order of 30%.
Monte Carlo can also be used in retrospective studies [52] [53], where the impact of inter-seed scattering and attenuation effects in prostate permanent implant
therapy was investigated. The study also examined the dosimetric effects of heterogeneous materials, such as prostate calcifications, which have been shown to
significantly alter doses. As above, a voxels mass density and elemental compositions are determined by converting CT numbers. The study found that, in general,
TG-43 U1 was over estimating the dose delivered to the target volume compared to
Monte Carlo simulations and that these doses were varying considerably between
patients.
Geant4 is a particle physics toolkit powered by the C++ language [54]. It
comes pre-loaded with physical data and processes as well as a framework to create
realistic environments based on geometric structures and contains multiple physics
models to account for photons, leptons, hadrons and ions with energies from 250 eV
to the order of PeV. Geant4 can also model detector response and brachytherapy
sources and output data visually, quantitatively and in terms of dose deposited.
Geant4 has been used in a number of publications to model brachytherapy seeds in
heterogeneous mediums. Previously, these types of calculations have been conducted
using Monte Carlo, however the large computation time of such models is such
that their use is not widespread [55]. Geant4 has the advantage of being designed
for such uses and with the installation of packages has libraries of information for
the simulation to draw from rather than re-computing parameters for each model.
Cuts, or energy thresholds can be set for secondary photons, electrons and positron
production. These characteristics make Geant4 well suited to modelling in medical
physics.
The Livermore package is a library for photons and electrons from 10 eV to
100 GeV for photon processes and is based on polarised processes [54]. Atomic
shell structure and shell cross-sectional data is directly used for calculations in this
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package, as low energy interactions are particularly influenced by these elements.
Libraries used for this package include the following information:
• Cross sections for photoelectric effect, Compton and Rayleigh scattering, pair
production and bremsstrahlung, including integrated subshell cross-sections
for the photoelectric effect and ionisation
• Energy spectra of the secondaries for electron processes
• Scattering functions for Compton effect
• Subshell binding energies and transition probabilities between the subshells
for fluorescence and the Auger effect
Physical processes modelled using this package are based on the information
contained in the libraries mentioned above, but also analytical evaluation of the
library data.
Lemarchal et al 2015, simulated seeds by organising physical layers in nested
layers. The photons were randomly placed onto the iodine layer with a random
trajectory and energy, and were then sampled. The study by Lemarchal found that
when modelling seeds accurately based on their physical composition and multiple
layers, the dose deposited to 90% of the volume of interest (D90) decreased by 3.2%
relative to TG-43 U1 formalism. With an overall difference of -8.71% in Geant4
when compared to TG-43 U1.
Previous studies have evaluated Geant4 models of Oncura 6711 brachytherapy
seeds relative to the gold standard TG-43 U1 [53]. The agreement between the two
calculation models were within 5%within 50 mm of the source. The Pope et al 2015
study measured the impact of prostatic calcifications on many dosimetric parameters
relative to the prediction of TG-43 U1 calculations. It was found that the presence
of these calcifications lead to a dose escalation proximally from the source to the
calcification and a dose decrease on the distal side due to the attenuation of the
relevant photon energies by the high Z components found in prostatic calcifications.
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The overall effect was a decrease in D90 by 2-4% for very small calcification volumes
relative to the volume of the prostate. However, the clinical significance of this
decrease in D90 is minimal.

2.10

The Eye Plaque Quality Assurance System

The Eye Plaque quality assurance protocol required a number of devices to collect
and interpret data and then to output the dose rate at a certain point. The following
are equipment developed by the Centre for Medical and Radiation Physics (CMRP)
previously.

2.10.1

Eye Plaque Probe

The Eye Plaque Probe is a small spectroscopic detector aimed at collecting the
spectra of the emitted photons and measuring the dose rate of low activity sources
[6], as shown in Figure 2.17. It contains a 1 mm3 p-type PIN diode mounted onto a
pre-amplifier board. The detector is run on a low bias of approximately 25 V. This
results in the formation of an even depletion layer whose thickness is of the order
of around 100 µm. The probe holds the detector rigid with a small ceramic frame
which acts both to protect the detector from physical damage and to hold it in a
fixed location. A Field Effect Transistor (FET) amplification system is employed to
boost the original signal before reaching the pre-amp. The pre-amp integrates and
amplifies the signal through to the read-out unit for analysis.
The small sensitive volume of 100 µm contributes to a high spatial resolution,
which is of paramount importance when measuring depth doses. A course spatial
resolution will result in less accurate depth dose profiles, particularly at the shallow
depths as they contain very steep dose gradients that are of great dosimetric interest.
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Figure 2.17: Original Eye Plaque Probe. The white tip approximates the position of the detector within the casing

2.10.2

Microprocessor Unit

The microprocessor unit was also designed and developed at the CMRP and was
constructed to interpret raw dosimetry data from I-125 brachytherapy seeds. It
contains a shaping amplifier and an on-board microprocessor and is pictured in
Figure 2.18. The shaping amplifier receives an electronic pulse from the pre-amp
and further amplifies the signal while shaping it into a Gaussian curve. The signal
is then passed through to the microprocessor. There is a pulse-height threshold that
is set with a manual dial adjustment where if the electrical pulse does not reach that
threshold, the signal will not be recorded by the system. A pulse-by-pulse counter
mode is employed by the microprocessor. An induced current counting method
would be inappropriate as the very low activity of I-125 sources would not allow for
the build-up of charge necessary for the registration of a count. Pulse-by-pulse also
has the advantage of allowing spectroscopic analysis of the signal as the energy of a
photon is proportional to pulse height allowing counts to be binned per their energy.
I-125 brachytherapy seeds emit a spectrum of energy, including photons from
both the fluorescence X-rays formed from the excitation of the seed’s titanium shell
and γ-rays from nuclear reactions from the nuclei of the I-125 source, although the
extent of the latter’s effect are minimal. This presents a difficulty in calculating
the dosimetry from such a source due to each energy photon contributing a differ-
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Figure 2.18: Microprocessor unit and dose calculation system

ent amount of dose. The pulse-by-pulse method allows for individual pulse height
information to be used, such that counts not originating from the brachytherapy
seeds, can be discarded. The microprocessor then achieves a dose calculation by
using an approximation to simplify the process. Previous studies [47] concluded
that the Iodine-125 brachytherapy seed spectrum can be averaged such that each
count represents the energy 27 keV. Only due to the very low energies considered
(in the ranger of 20-35 keV), the relative symmetry of the spectrum and that the
average energy occurs at the most intense photopeak, can this approximation take
place while calculating the dose with accuracy.
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Chapter 3
Testing of the Spectroscopic Eye
Plaque Probe
During the process of characterising the QA system any inconsistencies in dose
measurements, angular dependencies or deviations from expected TG-43 U1 trends
were investigated.

3.1

Single Seed Calibration

In order to acquire reliable and accurate measurements from the eye plaque probe,
it first had to be calibrated to TG-43 U1 specifications. Without this calibration the
probe would not be dosimetrically viable and therefore could not be used to gather
data accurately.
A single seed was used in this calibration as the dosimetry from one source is
simpler and more easily recreated when compared to 10 seed plaque measurements.
The test was conducted in a custom water bath where the seed is at the bottom of the
container as shown in Figure 3.1. Slabs of solid water were banked underneath the
phantom so as to ensure that any scatter from below the bath would replicate that
occurring in water. The detector was set-up to be directly centred and perpendicular
to the seed so as to eliminate any anisotropy and angular dependencies. The initial
measurement of the dose rate was taken at 3.5 mm. This 3.5 mm is relative to the
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Figure 3.1: Experimental set-up for the single seed calibration

detector sensitive volume and not the tip of the detector itself. The dose rates were
recorded at 0.5 mm increments up to 15 mm. At each dose rate increment, the dose
rate was displayed by the read-out unit.
The statistical analysis involved in the evaluation of each of the physical dose
rate measurements was achieved by acquiring a minimum of three independent readings, x. The standard deviation of the mean was used to account for the experimental uncertainties, as it expresses the spread and stability of the data acquired. The
uncertainty in the average of the three readings, ∆(x), is expressed in the following:

∆(x) =

r 
σ 2
x

;

(3.1)

where σ is the standard deviation. When normalising the data to values obtained
at 10 mm, the error was calculated by expanding the above equation:
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∆(x) =

s
 σ 2
x


+

σ10mm
x10mm

2
;

(3.2)

The method outlined above for determining the uncertainty of measurements
was completed for all experimental data collected for the entirety of this thesis.

Figure 3.2: Dose rate calibration of eye plaque probe, showing the agreement
between TG-43 U1 and experimental measurements

The probe was calibrated by adjusting the gain of the read-out unit such that
it matched the TG-43 U1 calculated dose at that depth. This was performed at
10 mm from the detector to the seed and was not adjusted at any time after. The
calibration depth dose profile very closely resembles the TG-43 U1 calculations over
the same distances as represented by Figure 3.2.

3.2

Plaque Measurement

Once the single seed calibration had been completed, the full plaque preliminary
testing was initiated. The setup for this experiment was almost identical to the
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single seed calibration aside from utilising a plaque loaded with 10 seeds. This
plaque was placed in the mould at the bottom of the water bath. The probe was
then positioned to be centred and perpendicular to the middle of the plaque, not
to any seed. The design of the ROPES plaque is such that there should be a
uniform dose from all directions along this central axis. All of the seeds loaded into
the plaque were from the same batch and should therefore have the same activity,
although realistically there was likely to be negligible fluctuations in the activity of
the seeds.

Figure 3.3: Experimental results with respect to TG-43 U1. Under-response
present in the shallow depths

Similar to the single seed set-up, the depth dose was taken using the read-out
unit, acquiring for 10 seconds. The probe was initially positioned at 0 mm from
the applicator surface, which would be approximately 3.5 mm from the sensitive
volume itself. The water bath was then lowered down in 1 mm increments and
three measurements were taken at each depth and then averaged. The results of
the depth dose were then graphed as seen in Figure 3.3. Here, there can be seen
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an under-response present in the shallow depths, which was not observed with the
single seed calibration.

3.3

Shallow Depth-Dose Effects

During characterisation it was discovered that the probe displayed an under-response
in the dose rate for shallow depth dose conditions. To investigate this further, the
geometry and layout of the eye plaque was investigated by completing depth doses
with just the outer ring of the applicator filled brachytherapy seeds, followed by a
depth dose of just the inner ring, both of which have been visualised in Figure 3.4.

Figure 3.4: Diagram of the inner and outer eye plaque circles. Seeds 1, 2 and 3
are a part of the inner circle and are in green, while seeds 4 to 10 make up the
outer circle and are shown in orange

3.3.1

The Inner Ring of Seeds Only

Using the calibrated probe and setup identical to the one used for the full plaque
tests, the inner ring of seeds were loaded into the plaque before being placed into
the mould at the base of the water bath. The probe was fixed into position above
the plaque and the water bath lowered to facilitate the change in depth as done
previously. Each depth dose was recorded 3 times on 10 second acquisitions and
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the results averaged to minimise random fluctuations. The depth dose was then
graphed relative to TG-43 U1 calculations for the inner ring of seeds only.

Figure 3.5: Comparison between TG43U1 calculations and inner ring experimental data

A good agreement between the inner ring of seeds and the TG-43 U1 calculation
can be seen in Figure 3.5. However, the measurement taken closest to the plaque,
where each seed subtends the greatest angle relative to the probe has shown an
under-response. This could suggest an angular dependence of the detector, therefore
the dose due the outer ring of seeds will be investigated to confirm this. The outer
ring of seeds subtends an even greater angle than the inner and should therefore
give a more definitive result.

3.3.2

The Outer Ring of Seeds Only

Using the calibrated probe and setup identical to the one used for the full plaque
tests, the outer ring of seeds were loaded into the plaque before being placed into
the mould at the base of the water bath. The probe was fixed into position above
48

the plaque and the water bath lowered to facilitate the change in depth, as done
previously. Each depth dose was recorded 3 times on 10 second acquisitions and
the results averaged to minimise random fluctuations. The depth dose was then
graphed relative to TG-43 U1 calculations for the outer ring of seeds only.

Figure 3.6: Comparison between TG43U1 calculations and outer ring experimental data

There is a marked under-response at the shallow depth as seen in Figure 3.6,
that then improves as the distance increases until the measured results are in line
with what is expected, suggesting that the probe had an angular dependence. The
position of the detector relative to the angles of the photons counted is visualised
in Figure 3.7. There were a number of explanations for this dependence. Firstly,
within the probe the detector is supported by a ceramic frame. This frame holds
the detector rigid, but also could be blocking some of the incident photons coming
in perpendicular with respect to the detector.
Another factor influencing the angular dependence is the orientation of the detector within the probe. The detector was mounted on it’s side such that the sen49

Figure 3.7: Range of primary photons that the detector is exposed to, by I-125
brachytherpy seeds, at differing depths

sitive volume has more attenuating material on one side compared to another and
this would be limiting the number of incident photons from certain angles.
Separate to angular dependence, there are some issues with the accuracy and
validity of TG-43 U1 at very shallow depths. The formalism does not take into
account the photons that are absorbed by their encapsulating material, the seeds
used in this experiment were contained in titanium. Other factors influencing this
result include the absolute positioning of the detector over the plaque as a very
small deviation from the central axis can cause significant differences in the dose
rate measured, particularly at those small distances.
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3.4

Discussion

The initial characterisation of the probe exposed a number of issues. Due to the
angular dependence displayed by the probe at shallow depths it was not appropriate
for use in Eye Brachytherapy quality assurance procedures. The shallow depth doses
contain sharp dose gradients and therefore need to be recorded with accuracy and
confidence. However, it was found to be successfully characterised following TG-43
U1 protocol for single seed sources, which by extension makes it suitable for the
dosimetry of radiation sources not containing an angular component.
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Chapter 4
Design and Testing of Motorised
Positioning System
4.1

Implementation

The eye plaque probe that was characterised showed many signs of having an angular
dependence. This would make it unfit for use as an eye plaque probe due to the
wide range of angles the photons originate from within an eye plaque.
In order to confirm this was the case under more accurate circumstances; a
motorised linear stage, coupled to a rigid, aluminum stand replaced the simple
hand-wound stand as the depth control. This system would hold the probe in the
same xy position relative to the phantom and plaque, while moving it up in steps
with pre-determined sizes with micrometer accuracy. The introduction of the system
pictured in Figure 4.1, removes the positioning uncertainty as a source of error.
Due to good results obtained from the single seed characterisation using the
manual stage, only plaque measurements were conducted. The simple water bath
was used in the following measurements, not the full eye plaque phantom as it
introduced new inaccuracies and did not relate to the determination of whether the
plaque had angular dependencies.
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Figure 4.1: Drawing of the motorised gantry with the eye plaque phantom and
probe in place

4.2

Full-plaque Tests

The set-up for the motorised stage required a similar procedure to the previous
experiments, as picture in Figure 4.2. The plaque was placed at the bottom of the
water bath into the mould. Solid water was banked under the water bath and the
linear stage driven to it’s zero position. The probe was fitted into the gantry by
placing it in the holder and positioning it such that the tip was just touching the
plaque insert, the screws around the holder were then tightened to hold the probe
rigid and in place. The probe was also connected to the read-out unit as before.
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The gantry’s display was then used to set the step distance, which was 0.5mm, and
that prompting was required before any movement would commence.

Figure 4.2: Picture of the motorised stage controlling the z position of the eye
plaque probe

The dose according to the read-out unit was recorded at each depth, with three
10 second acquisitions averaged to give the dose. An MCA was also utillised so as
to reduce any error stemming from the read-out unit. The results of this acquisition
are seen in Figure 4.3.
These results were compared to TG-43 U1 calculations. The use of the motorised
gantry has resulted in data that conforms more closely to the TG-43 U1 prediction
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Figure 4.3: Depth dose profile combining the data from both experimental
sources and from TG-43 U1

than what was found previously. However there can still be seen a slight underresponse of the dose rate at shallow depths, consistent with what was found with the
original gantry. The angular dependence of the probe would most likely contribute
to this deviation and will be further investigated by analysing the depth dose profiles
of the inner- and outer-seeds separately, while using the motorised gantry.

4.3

Inner-plaque

After all but the three inner-ring seeds were removed from the plaque, the same
experimental conditions as seen in the full-plaque tests including the motorised positioning system were set up. Similar to the previous experiment, 0.5 mm increments
for depth dose were set and the probe situated as close as possible to the plaque
along it’s central axis. The method of recording the depth dose via the read-out
unit and through spectral analysis also remained consistent with previous tests. The
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depth dose was recorded in Figure 4.4.

Figure 4.4: Inner Plaque depth dose profile comparing the read-out and spectral
doses with TG-43 calculations

The dose-rate acquisition shows a good agreement with the theoretical TG-43
U1 predictions. However, there is a slight under-response of the read-out unit on
the distal part of the graph, however the results were within experiment error. Due
to the dose rate being collected using the read-out unit’s microprocessor, it can be
concluded that with such low-activity sources the acquisition time of 10 seconds for
the read-out unit is insufficient.
Similar to the results obtained with the simple gantry, a minimal under-response
was seen between the read-out dose and the TG-43 U1 calculation in the depth dose
of the inner-ring of seeds. Therefore, to determine if the eye plaque probe has
angular dependency issues the outer-ring of seeds were re-tested with the motorised
positioning system.
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4.4

Outer-plaque

The set-up and acquisition was identical to the inner-plaque experiment. A larger
under-response of the system can be seen in the outer-plaque measurements. This
suggests that there is an angular dependence, as the under-response was not seen
when measuring the dose rate from just the inner-plaque seeds. The results are seen
in Figure 4.5.

Figure 4.5: Depth dose profile comparing the read-out and spectral doses with
TG-43 U1 calculations

4.5

Discussion

Even with the improved positioning system, the under-response of the probe in
the shallow depths is visible. From this it was concluded that the rudimentary
positioning system improved the results, making them more accurate, but did not
inherently change them. It was reasonably concluded that the probe was affected
by angular dependence issues.
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It therefore was necessary to build a new detector system, one that was not
affected by angular dependence.
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Chapter 5
Design of the New Probe
A lack of accurate and reliable results obtained from initial characterisation, made
clear that original eye plaque probe would not be a clinically viable device for eye
plaque quality assurance testing and that the system would have to be redesigned.
The new instrumentation would have to ensure angular dependence and localisation
difficulties would be minimal and would not influence the overall dose reading.

5.1

Detector

The first stage in the design of the new probe was to select an appropriate detector.
Similar to the one used previously, it would have to be small enough to both place at
the tip of the probe and for it’s spatial resolution to be sufficiently small. It would
have to be compatible with the same circuitry system in the old probe and be able
to acquire radiation in pulse mode. The most important feature of the detector was
that it would have to be angular independent. Not only in photon collection, but
in overall probe design. It could not be made rigid using a ceramic frame as done
previously.
The detector selected was an edgeless detector as shown in Figure 5.1, it is
made of n-type substrate and with p+ and an n+ junctions. One of the primary
features of an edgeless detector is that one of the electrodes extend around the
silicon substrate volume almost encapsulating it. The result of which is a detector
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Figure 5.1: Diagram of edgeless diodes where a) is the PN and b) is the NN
configuration

which is angular independent as the sensitive volume of the detector should be
approximately uniform in thickness in all directions. The edgeless design does come
with some issues, however. The relatively small distance between the two electrodes
means that the detector has a high surface current. This requires the bias voltage
to be low.
The diode used in the final probe was selected from the batch, all of thickness
0.1mm. Each detector had a slight variation in size or in configuration as shown in
Table 6.1. Each of these detectors underwent testing to acquire I-V characteristics
and spectral measurements at difference bias voltages. The diode with the most
favourable characteristics, such as energy resolution and charge collection efficiency
was chosen for use in the probe.
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Table 5.1: Edgeless Diode Specifications

Type

Configuration

Dimensions

NN1 XSP

N+ on N

0.5 × 0.52

NN1-18 MS

N+ on N

1.5 × 1.52

NN1-18 MP

N+ on N

1.5 × 1.52

PN1-56 XS

P+ on N

0.5 × 0.52

PN1-56 S

P+ on N

1 × 12

PN1-56 M

P+ on N

1.5 × 1.52

NN2-32 XSP

N+ on N

0.5 × 0.52

NN2-32 SS

N+ on N

1 × 12

NN2-32 MP

N+ on N

1.5 × 1.52

Figure 5.2: NN1 IV Characteristics

5.1.1

I-V Characteristics

Each of the detectors in the batch were tested to obtain their I-V characteristics,
investigating the detectors suitability for use in the probe by determining the impact
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of surface current and noise on their output signal. The output was measured over
10V in a reverse-biased configuration as shown in Figure 5.2, 5.3 and 5.4 for the
NN1, NN2 and PN1 models respectively.
All of the detectors were depleted over a very small voltage range, of the order
of 0.5 V. Generally, currents lower than 10 nA are able to be used in dosimetry, as
above such levels the leakage current begins to dominate the signal. The majority
of the NN diodes showed a high current response over very small voltages. This
unfortunately precludes them from being used in the probe as any bias voltage
would result in an unsuitable current. In addition to the magnitude of the current,
the shape of the detector response is significant when considering a bias voltage in
which to operate the detector. A relatively flat region relative to voltage would
be preferred, as it would have a leakage current less sensitive to any variation in
voltage.

Figure 5.3: NN2 IV Characteristics
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Figure 5.4: PN IV Characteristics

5.1.2

Spectral Characteristics

In addition to the IV characteristics, the spectral characteristics of the batch were
measured using an I-125 source in a shielded container.
The spectra shown in Figures 5.5 and 5.6. The NN detectors were operated with
a bias voltage of 6V, while the PN diodes 5V. Following results of the IV characteristics taken, the high currents displayed by the majority of the NN configured diodes
have made them unsuitable for spectroscopy. Detectors NN2-32 XSP, NN1 XSP
and NN1-32 MS/2 displayed currents of less than approximately 5nA when operated at 6V in the IV curves and were the only of the NN configured diodes to do so.
They were also the only detectors that output an observable I-125 spectrum from
that group. The energy of the NN diodes is course and does not show many of the
features of the expected spectrum, including many of the well-defined photopeaks.
The PN configured detectors output significantly better spectra. All but PN156 M/1 output a current less than approximately 5nA when operated at 5V in the
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Figure 5.5: NN configured diode measured spectra operated with a bias of 6V

Figure 5.6: PN configured diode measured spectra operated with a bias of 5V
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IV curves, which resulted in well defined I-125 brachytherapy spectrum. The energy
resolution of the spectra shown in Figure 5.6 is excellent as even low intensity photo
peaks such as the 25 keV can be easily distinguished.

Figure 5.7: Diagram showing the depletion of edgeless diodes under reverse-bias
conditions where a) is the PN and b) is the NN configuration

The PN-type diode was shown to be significantly superior to the NN configuration when operated at the chosen voltages. The depletion layer within the bulk N is
dependent on the configuration of the diodes, for example with the NN configuration
the reverse bias depletes the detector from the outer P+ region in towards the N+,
while the PN is depleted from the central P+ to the outer N+, as shown in Figure
5.7. The NN configuration results in high levels of leakage current, resulting in a
65

very poor energy resolution of the spectrum and very high levels of noise.
There were a number of potential candidates from the PN diodes to be used in
the probe. In order to ascertain the most appropriate one, both the relative efficiency
and the full width half maximum (FWHM) of the 27keV peak of the detectors were
compared in Table 6.2. The relative efficiency of the detector was determined by the
spectral channel number of the centroid, where the higher it is, the more efficient
the detector.
Table 5.2: PN Diode Efficiency and Energy Resolution

Type

FWHM (V)

Centroid Voltage

PN1-32 XS1

0.2302

4.075

PN1-32 XS2

0.2205

4.343

PN1-56 S1

0.1906

4.493

PN1-56 S2

0.2028

4.463

PN1-56 M2

0.2576

3.211

From this simple analysis, it can be seen that most appropriate diode from the
batch, with both the most favourable efficiency and energy resolution is diode PN156 S1, closely followed by PN1-56 S2. As this detector has the smallest FWHM and
highest centroid channel of the selection.
The diode chosen will therefore be operated at approximately 4.5V. This voltage
gives a good combination of energy resolution and charge collection efficiency.

5.2

Diode Housing

In order for the sensitive volume to be uniform in all directions, the detector has to
be bonded to the probe as shown. This method of bonding required the design of a
completely new probe tip in order to facilitate the new detector.
A new PCB design allows the detector to sit with the p+ electrode facing outwards, as shown in Figure 5.8. This does limit how close the detector can get to
the surface of the eye plaque due to simple geometry. A 3D-printed probe tip was
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designed but was limited by the curvature of the plaque itself and by a minimum
thickness. The radius of the inner surface of the probe tip in 10.4mm, this curved
surface will restrict the proximity of the detector to the plaque, shown in Figure 5.9.
The diagonal length of the PCB was calculated to determine the placement of the
detector withing the probe.

Figure 5.8: Maximum length dimension of PCB Detector board

Hypotenuse2 = 4.30mm2 + 4.73mm2
√
Hypotenuse = 40.8629mm2
= 6.39mm
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Figure 5.9: The detector position within the probe due to geometric limitations

Using half the maximum length of the PCB and the radius of curvature of the
inner surface of the probe tip, the minimum distance the detector can sit from the
tip of the probe can be calculated.

b = 3.1962mm, c = 10.4mm;

c 2 = a2 + b 2
√
a = c 2 − b2
= 9.896mm
d=c−a
= 10.4mm − 9.897mm
= 0.504mm

With the plastic probe cover being 5mm thick and the detector itself 0.1 mm,
the minimum distance the centre of the detector can be from the outer surface of
the probe tip is 0.954 mm. A rendering of the probe casing can be seen in Figure
5.10.
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Figure 5.10: A computer rendering of the 3D-printed probe casing

5.3

Probe Construction

The construction of the probe was a delicate process as the wire-bonding of the
detector is very fine and fragile. Figure 5.12 shows how the PCB with diode attached
was perpendicularly bonded to the probe circuit board such that once connected it
would operate in a reverse bias configuration.
Next, the housing for the preamplifier was constructed including the aluminum
cylindrical cover, and the 3D-printed probe tip as well as the cabling being assembled. Initial tests for the probe were conducted within a small Faraday’s cage, that
also blocked any incident visible light. Good results were seen, however once the
probe was removed a lot of noise was being recorded. The noise was most likely
due to insufficient radio-frequency and light shielding of the probe. The 3D-printed
probe tip was translucent. This was remedied by coating the plastic cover with a
thin layer of nickel paint, sealed with an enamel paint, thus eliminating the rf and
light interference. An aluminum strip was placed between the nickel-covered probe
tip and the preamplifier housing, with a heat-shrink rubber used to hold it firmly in
place. The finished product can be seen in Figure 5.11.
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Figure 5.11: Photo of the finished probe, complete with the nickel layer and
black enamel paint

Figure 5.12: Diagram of reverse-biased detector arrangement of the probe with
a) the PCB with the diode configuration is pictured and b) the pre-amp connectors
shown at the bottom
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Chapter 6
Geant4 Simulations
6.1

Verification

After the design and construction of the new probe, the Geant4 toolkit was utilised
in a modeling process and eye plaque simulations were conducted. This was in
order to verify and ensure that our new designs would work well, particularly with
photons incident from a wide range of angles. For each simulation, the Livermore low
energy electromagnetic physics model was used. The simulation included models of
the photoelectric and Compton effect, gamma conversion, Rayleigh scattering and
Bremsstrahlung radiation, as well as a default cut value of 0.001 mm, a low energy
threshold of 250 eV and a production threshold range of 0.1 mm. The output of
the program was both the overall deposited dose in the silicon volume as well as a
spectrum of 400 channels, with a bin width of 0.1 keV. These settings, particularly
the small cut value and energy threshold, were chosen to effectively model the low
energy photons emitted by I-125 brachytherapy seeds.
A simulation containing a fully formed ROPES eye plaque was used in testing
simple detector volumes as seen in Figure 6.1. Initially the simulations were relatively simple; A stainless steel eye plaque applicator, acrylic mould insert and 10
Iodine-125 seeds loaded into the insert were all included in the plaque simulation
code as well as a small 0.5 x 0.5 x 0.5 mm3 silicon detector volume all situated
within a large, cylindrical water phantom, as shown in Figure 6.1. A total of 2 × 109
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Figure 6.1: Visualisation of eye plaqe and simple detector volume in Geant4

incident particles originating from the seeds were modeled.
The data was then analysed by comparing the dose output and by integrating
the spectra produced. Utilising the spectral component of the program was a better
representation of the QA system’s read-out and included channels 20 keV to 40 keV
to mimic the energy window seen in the electronics. Both doses were the normalised
and compared.
The data extracted from the GEANT4 simulations used a similar error analysis
as was used for experimental measurements. However, the simulations used counts
assigned to a single energy to determine the dose and then normalised to the values
obtained at 10 mm. The measurement uncertainty, ∆Nx , was determined by the
√
square-root of the counts in each bin, Nx , as defined in the following equation:
s √

∆Nx =

Nx
Nx

2

√
2
N10mm
+
;
N10mm

(6.1)

It can be seen in Figure 6.2 that Geant4 and TG-43 U1 do not agree exactly at
shallow depths. This could be due to some inherent shortcomings of the TG-43 U1
formalism. Firstly, the TG-43 U1 calculation only includes the I-125 brachytherapy
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Figure 6.2: Depth Dose profile using both TG-43 U1 calculations and a Geant4
model. The model includes ten I-125 seeds, a stainless steel plaque with an acrylic
applicator. The detector volume is silicon

seeds and not the extended environment in the Geant4 simulation. The presence of
the stainless steel applicator and the acrylic insert are not taken into account, with
the former contributing to a higher dose in shallow depths due to low energy photons
being back-scattered from the high Z material unlike its behaviour in water. Other
shortcomings of TG-43 U1 include the definition of Air KERMA being in vacuo.
This means that any calculation conducted in any medium must be corrected. In
addition to this, TG-43 U1 formalism is more appropriate for determine the dose at
larger distances than the ones being considered above. TG-43 U1 measures the dose
deposited in water, while the volume used in the simulation better approximated
the material of a silicon detector, which would also contribute to a discrepancy in
dose.
To confirm this analysis, the materials of the plaque applicator, insert, and the
detector volume were changed to being comprised water in the following simulation.
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The distances considered in this simulation were also made to be 0.25 mm increments
so as to more reliably represent a depth dose. The spectral analysis of the simulation
was not conducted in this test.

Figure 6.3: Depth Dose profile using both TG-43 U1 calculations and a Geant4
model. The model includes ten I-125 seeds, with all other structures defined as
water

The simulation, as seen in Figure 6.3, shows a closer agreement between the
Geant4 model and TG-43 U1 calculations. This confirms that TG-43 U1 does not
allow for heterogeneities such as the stainless steel plaque. Therefore the Geant4
model will be used as the calibration baseline for the probe, with TG-43 U1 being
a reference tool.

6.2

PCB Model

Construction of the probe using Geant4 modeling was performed in stages in order to
evaluate each components contribution to the depth dose profile. Firstly, a realistic
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detector and PCB were constructed. The board itself was modeled to be made of
acrylic, and each of the contacts, gold. With the ceramic scaffold being on of the
main sources of angular dependence with the probes old design, the tip of the new
prototype was redesigned. The new design required the detector to be mounted to
a circuit board at the tip of the probe, sitting perpendicular to the PCB.

Figure 6.4: Geant4 Visualisation and the schematic of the PCB

Although this led to a large reduction in the angular dependence of the probe,
the gold contacts could still attenuate the incident photons sufficiently to reduce the
dose at shallow depths.In these simulations the eye plaque and applicator were set to
stainless steel and acrylic respectively, while the iodine seed composition remained
unchanged from previous tests. The detector mounted to this board was then modelled to approximate the effect that the gold components had on the edgeless diode,
the visualisation of the PCB construction can be seen in Figure 6.4.
Figure 6.5 displays the close relationship between the simple water volume and
the response of the PCB with mounted detector. There is a slight under-response in
the shallow depths, this could be due to the gold components of the board providing a
medium for attenuating incident photons, reducing the signal reaching the detector.
The spectrum modeled by the simulation of the detector board was then compared
to that acquired experimentally, as seen in Figure 6.6.
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Figure 6.5: Depth Dose profile using Geant4 models of the PCB and the simple
silicon volume

The Geant4 model seems to predict the majority of the photo peaks seen in the
experimental spectrum, including those peaks formed due to the fluorescence of the
gold, detector board components.
One of the drawbacks of the detector board was that the detector itself was not
mounted in the centre of the board but offset. This offset was added to the code such
that the detector was centred about the central axis of the plaque. The detector
board also limited the proximity of the detector to the eye plaque at the corners
formed by the rectangular board hit the concave surface of the plaque applicator.
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Figure 6.6: Geant4 simulation of the new probe’s measured spectrum compared
to that measured experimentally

6.3

New Probe Model

Finally, the detector cover was added to the Geant4 model of the new probe, as
shown in 6.7. A series of concentric cylinders, with a concave tip was created to
simulated the nickel-coating, the 3D-printed plastic and the air surrounding the
detector board. The latter was placed within the housing such that the detector
was as close to the external tip of the probe as was physically possible in real life.
The nickel layer was approximated to a thickness of 0.01 mm, while the 3D-printed
plastic was approximated to an acrylic material, as the exact composition of the
plastic was not released by the manufacturer.
The response of the fully realised new probe was then compared against a simple
water volume as shown in Figure 6.8. The probe showed little to no radiation opacity,
even with the addition of the nickel paint layer. It also appeared to be minimally
angularly dependent, even with the presence of gold components within the detector
board. There is, however, an over-response of the probe at 1 mm. It was unclear
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Figure 6.7: Geant4 visualisation of the complete new probe next to the model
of an eye plaque

why this is occurring, so a second simulation was run without the nickel-paint in
order to quantify its dosimetric impact.
There are multiple reasons for examining the impact of this component as a
high proportion of photons in the keV low energy range have a high probability of
undergoing the photoelectric effect when interacting with matter, where the extent
of this effect is significantly influenced by the atomic number or Z of the medium
and nickel has a significantly higher atomic number than water.
Figure 6.9 closely compares to the water volume case, along with Figure 6.8.
Together they show that the response at a distance of 1 mm was due to the presence
of nickel. This was definitively not from nickel fluorescence, however, as its k-shell
characteristic x-rays occur at approximately 7.4 keV and was therefore not counted
in the dose calculation due to an energy threshold of 20 keV. The case without nickel
shows a slight over-response, potentially due to the presence of air in the probe tip
above the detector. The air, being a low density material allows more photons to
scatter in but not scatter out, increasing the intensity of photons incident on the
sensitive volume and thus increasing the signal.
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Figure 6.8: Comparison of Geant4 simulations of the depth dose from a eye
plaque of the new Eye Plaque Probe and of a simple water volume
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Figure 6.9: Comparison of Geant4 simulations of the depth dose from a 10 seed
eye plaque of the new eye plaque probe without a nickel coating and of a simple
water volume

Figure 6.10: Comparison of Geant4 simulations of the depth dose from the inner
seeds eye plaque of the new eye plaque probe and of a simple water volume
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6.4

Angular Dependence

The potential for any angular dependence was investigated by comparing the full
probe response, with and without the nickel paint, to simple water volumes, for both
the inner- and outer-seed plaque cases.

Figure 6.11: Comparison of Geant4 simulations of the depth dose from the inner
seeds eye plaque of the new Eye Plaque Probe without a nickel coating and of a
simple water volume

Both Figures 6.10 and 6.11 show a close comparison to the dose response of
a water volume. Similar to the full plaque case, the inner plaque shows the same
over-response at 1 mm with the presence of nickel, but does not show slight change
in response shown in Figure 6.11.
It can be seen in Figure 6.13 that the outer plaque reading with the new probe
conforms well to the water volume case, despite the presence of air in the simulation,
which did not appear to introduce any angular dependencies. Figure 6.12 however,
shows a large deviation from the water volume. The nickel appears to attenuate the
primary photons from the outer seeds more than those from the inner seeds.
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Figure 6.12: Comparison of Geant4 simulations of the depth dose from the
outer seeds of an eye plaque of the new eye plaque probe and of a simple water
volume

Figure 6.13: Comparison of Geant4 simulations of the depth dose from an eye
plaque of the new eye plaque probe without a nickel coating and of a simple water
volume
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This may be due to the photons from the outer seeds traversing through a greater
thickness of nickel as a result of obliquity. Due to the relatively low dose contribution
from the outer plaque photons to the full plaque, the latter still conforms closely
the water volume case.

6.5

Discussion

The series of simulations performed have validated the design and components of
the new probe for use in eye plaque brachytherapy dosimetry. The over-response by
the 1 mm position should not influence clinical measurements, as the phantom limits
the possible proximity of the probe to the plaque to 2 mm. As stated previously, the
under-response due to the angular dependence introduced by the presence of nickel
paints should not influence the full plaque measurements significantly. The outer
plaque demonstrated a stronger effect, however it contributes relatively weakly when
compared to the inner plaque. The true thickness of the nickel layer is unknown,
therefore is difficult to estimate the effect it will ultimately have on experimental
results.
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Chapter 7
Eye Plaque QA System
7.1

Eye Plaque Phantom

During correspondence with staff at Prince of Wales Hospital it became clear that
the eye plaque must remain sterile after the brachytherapy seeds are inserted so as to
reduce the risk of infection to the patient. This made the previous mode of testing
unable to be implemented into a hospital environment due to the plaque being
exposed to water and in no way encapsulated. Therefore, a new testing method
had to be formulated before the quality assurance system could be implemented
clinically.
The most appropriate way of maintaining the sterility of the plaque would be
to keep it in a completely separate compartment to the water. However, this caused
issues in the resulting dosimetry, as there would be a layer of material between
the plaque and the probe limiting the plaques ability to take surface doses. It was
concluded that as important close dose measurements are, the sterility of the plaque
could not be maintained in any other way.
The plaque container had to be as conformal as possible while retaining a waterproof seal. After many design attempts, the phantom depicted in Figures 7.1 and
7.2 was developed:
The new eye plaque phantom was developed with three separate pieces, designed
to maintain the sterility of the eye plaque and to achieve dosimetric outcomes. In
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Figure 7.1: Visualisation of the Eye Plaque Phantom. Including the large water
tank and two sterile plaque inserts. Phantom Legs excluded in rendering

Figure 7.2: Cross-section of the Eye Plaque Phantom. Displays the interlocking
pieces, including the plaque release mechanism. Legs excluded
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order to encapsulate the plaque in as thin as possible material, 3D printing the
phantom and its pieces was determined to be the most viable construction option.
The main water phantom is 140 mm deep and 175 mm in diameter water tank housed
on three supporting legs. The top area is to both be filled with water and will be
where the probe rests during measurements. This is a relatively large water area
compared to previous phantoms, this was to further emulate TG-43U1 conditions
and to reduce any outside materials influence on the data collected. Supportive
ridges were added to help the container with a full load maintain its shape. The
base of the tank is solid plastic up until the centre where there is a void. The
thickness of plastic at the edge of the void is just 0.5 mm which was the limit of the
3D printing construction modality.

Figure 7.3: Inserts for the Eye Plaque Phantom. The small cap fits on the top
of the large piece to maintain the sterility of the plaque during testing

The remaining two pieces fit together to house the eye plaque, and are specifically shaped to fit as compactly as possible. Both of the smaller pieces are able to
be sterilised along with the plaque as the plastic used in the 3D printing process is
able to comfortably withstand temperatures up to approximately 60◦ C. The smallest piece is the lid, shaped to the internal contour of the plaque and is just 0.5 mm
thick. Therefore when measuring using this phantom, just one millimetre of extra
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distance need be accounted for, whilst maintaining sterile conditions. The second
piece, or the plaque insert shown in Figure 7.3 holds the plaque, while the lid fits
tightly on top. It also has notches in its sides that sit in the ridges of the water
phantom to hold itself flush to the voids edge.

7.1.1

Spectroscopic Eye Probe Calibration Insert

In order to make the eye plaque phantom a versatile piece of equipment, a phantom
accessory has been designed and fabricated. The current Eye Plaque Brachytherapy
QA system requires calibrating with a single I-125 brachytherapy seed in order to
output an accurate dose rate measurement, however the inserts described above only
serve to hold the plaque in place. The calibration measurement is very sensitive to
the seeds position relative to the probe due to the sharp dose gradients of I-125
sources. A cap was designed to hold a single seed in the water phantom such that
the probe is always situated along the its central axis. The 3D printed cap, shown
in Figure 7.4 is made from the same material as the phantom and sits on top of the
depression analogous to the eye in water to achieve close to TG-43U1 conditions.

Figure 7.4: Eye plaque phantom accessory cap. The cap is designed to hold a
single seed for calibration purposes
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Chapter 8
Experimental Measurements
8.1

Characterisation

The introduction of new components when compared to the previous design, required an investigation into any characteristics of the acquired data from the probe.
In particular, an investigation into the resulting measured spectrum and angular
dependence of the new probe. Figure 8.1 shows the experimental set-up utilising
the new probe and the eye plaque phantom and Figure 8.2 shows the spectrum
measured using Oncoseed 6711 seeds with a very low activity of approximately 0.01
mCi.
The energy resolution remains superior to the old probe even within its housing, however a number of new peaks have formed in the low energy region of the
spectrum. These peaks are likely due to characteristic X-rays produced in the outer
nickel coating of the probe and the the gold components present on the PCB. As
they did not originate from the seed itself, we may ignore these when considering
their contribution to the dose to water from brachytherapy sources, which is an
advantage of a spectroscopic dose calculation system and energy thresholding.
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Figure 8.1: Picture showing the experimental set-up of the new probe driven
by the motorised position system, the eye phantom and read-out unit

Figure 8.2: Graph showing the spectrum of Oncoseed 6711 seeds as measured
by the new probe. Low energy characteristic X-rays resulting from the probes
nickel and gold components are represented by the three low energy peaks
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8.2

Single Seed

The new probe coupled with the automated positioning system had to undergo
verification before testing in a clinical strength, high-activity environment. The
probe was calibrated using a single seed and compared to TG-43U1 calculations.
The CMRP eye plaque phantom was used for the following measurements.
For the single seed experiment, instead of using the plaque holding insert the
seed was placed on top of the depression. Care was taken to ensure that the seed
was properly centered relative to the probe and the probes zero position was just
touching the seed. As mentioned previously the probe is limited by it’s plastic
protective sheath, and so the minimum distance it can be from the seed even when
zeroed, is 1.5 mm. The step size of stage was 0.2 mm for maximum sensitivity in
the high dose gradient regions.

Figure 8.3: Graph showing the normalised dose rate of a single seed measured
with the new probe, compared to TG-43U1 calculations

The experimental data shown in Figure 8.3 matches the theoretical calculations
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well and within error limits. The slight discrepancies between the two sets of data
are due to the localisation of the single seed relative to the probe. It is even difficult
to localised the source of radiation within the seed itself, as the silver rod implanted
with the I-125 can move within the titanium capsule. Very high dose gradients exist
in the area around the seed, due to the very low energy of the photons emitted,
making localisation of the seed all the more important.

8.3

Full Plaque

As the new probe performed well measuring the dose rate of a single seed with no
angular component, a full plaque measurement was conducted. The sterile inserts
were used to hold the plaque in place under the phantom, bringing the closest measurement to 2.5 mm from the diode to the plaque surface. The detector was initially
positioned touching outer surface of the phantom depression, each measurement was
taken at intervals of 0.2 mm.

Figure 8.4: Graph showing the normalised dose rate of a full plaque measured
with the new probe, compared to TG-43U1 calculations
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Figure 8.4 shows the depth dose as measured by the new probe. Similar to the
previous detector, the results are under-responding at shallow depths when compared to TG-43U1 calculations, suggesting an angular dependence is still present,
albeit very small.

8.4

Clinical Strength Measurements

Eye plaque brachytherapy, although being a low dose rate modality of brachytherapy,
can use relatively high activity seeds depending on the prescribed dose and duration
of treatment. Due to the pulse-by-pulse photon counting method employed by the
dose calculation system, there is the potential for dead time and dose pile-up to affect
the dose rate as measured by the probe. The following experiments were required
to verify that the calculation system could process the large dose rates from high
activity sources used clinical strength eye plaques.

8.5

Calibration

The calibration of the probe required the use of both the eye plaque phantom and
the single seed cap accessory in conjunction with the motorised positioning system.
Firstly, a seeds activity was measured in a well chamber and recorded before being
loaded into the single seed cap. The cap was then placed inside the phantom.
The probe was secured in the apparatus arm and lowered down so that it was just
touching the seed. The probe tip was then positioned 8.5 mm away from the surface
of the seed (the diode being 10 mm away), as this was the calibration position. TG43U1 calculations were completed using the measured seed activity and the gain of
the read-out unit adjusted, such that the dose rate output by the system matched
the calculation for a point 10 mm along the central axis of a theoretical single seed.
Once the gain had been adjusted, the dose rate was recorded at increments of
0.5 mm starting at 1.5 mm.
As done before in previous measurements, the uncertainties of the experimental
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data was determined by taking the average of 3 readings. When determining the
positional uncertainty of measurements, the smallest increment of the positioning or
measurement device can be considered to be the limiting factor of accuracy. Double
this increment was used to reflect positional uncertainty in this experiment.
These results were graphed and compared to the TG-43U1 calculations.

Figure 8.5: Graph comparing the dose rate of TG-43 U1 calculations and experimental measurements of a single seed

Figure 8.5 shows a relatively close comparison between the measured dose rate
and TG-43 U1 calculations. There is a slight discrepancy at the shallow depths
which is most likely caused by uncertainty of the diode position within the probe
tip. Although the plastic sheath has notches for the detector board to sit in, due to
the diode being located off-centre on the square PCB, it is likely that the diode is
not completely centered laterally within the probe. Any change in the distance and
position of the detector relative to the seed will result in significant deviations from
the expected dose-rate, due to the steep dose gradients characteristic of low-energy
radioactive sources such as I-125. Nonetheless the calibration for distances of 3 mm
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and above are acceptable for clinical plaque testing.

8.6

Full Plaque Measurement

Once the system had been calibrated using a known-activity source, it was ready
for full plaque verification testing. The plaque was loaded according to a treatment
plan and placed in the plaque-holding insert for the phantom, covered with the lid
and placed up into position within the phantom. The probe was lowered to be
just touching the upper surface of the plastic depression housing the eye plaque.
The dose rate was recorded at 0.5 mm increments, as done previously. Because of
the extra layers of plastic present between the plaque and the probe, the minimum
distance from the plaque to the diode was 2.5 mm.

Figure 8.6: Graph comparing the dose rate of a clinical plan and the experimental measurements of an eye plaque

The experimental dose-rate was compared to the clinical plan generated for
the treatment. It can be seen from Figure 8.6 that the the probe response closely
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matches the planned treatment. Data measured at 3 mm was found to be under
responding by 5.2%, but the calibration was sufficient for distances greater than
3mm. The majority of the other points were well within 1% of the planned dose
rate. These results confirm the eye plaque probe system as being a reliable dosimeter
for use in dose-rate verification for eye plaque brachytherapy.

8.7

Introduction of Errors

To further affirm the use of the system in clinical quality assurance an error was
introduced into the plaque itself and the measurements re-performed to substantiate
whether the system can detect set-up errors. Some of these set-up errors come in the
form of a misplaced seed within the plaque. As the plaque itself has few identifying
features and the seeds have none, there is potential for the physicist to place a seed
incorrectly within the applicator, and for that seed to alter the dose profile of the
plaque affecting treatment outcomes.

Figure 8.7: Diagram showing placement of seeds within the ROPES 10-seed eye
plaque, in particular the inner- and the outer-ring seeds numbered 1-3 and 4-10
respectively

For the first measurement, a plan was used with a mixture of 3.841 mCi and
1.556 mCi seeds. A central, high activity seed was replaced with a lower-activity
seed, which has approximately 40% the activity of the former. A diagram of the
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seed positioning can be seen in Figure 8.7. Because of the central position of the
introduced error, the probe is expected to detect the change without issue.

Figure 8.8: Graph comparing the dose rate of a plaque packed according to the
TPS and a plaque where a 3.841 mCi inner ring seed was replaced by a seed with
an activity of 1.556 mCi

A significant deviation from the planned plaque can be seen in Figure 8.8 particularly at distances of 2.5-6 mm, with a maximum deviation of 18%. This would
be significant enough to warrant the clinical physicist to investigate the plaque and
to re-measure the activity and placement of the seeds.
Further investigations were required to see if a misplaced seed from the outer
ring would register a significantly different depth dose. This time, a mixture of seeds
with activities of 4.022 mCi and 1.652 mCi were used in the plaque and a higher
than planned activity seed (approximately 240%), replaced an outer ring seed and
the plaque was re-measured.
Figure 8.9 shows that, even with a small difference between the activity of the
seed in the planned and packed plaque, the system is sensitive enough to register
the variation. A significant difference between data, approximately 6-9% at each
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Figure 8.9: Graph comparing the dose rate of a plaque packed according to the
TPS and a plaque where a 1.652 mCi outer ring seed was replaced by a seed with
an activity of 4.022 mCi

measurement point, can be seen even with the smaller contribution to the changing
dose rate due to the position of the seed.

8.8

Discussion

The newly designed probe responds well in a low activity environment. The spectrum collected was superior to the previous spectra produced using the old probe
and displayed a fine energy resolution where the peaks were easily resolved. The
high Z components of the new probe did not produce a signal that interfered with
the Oncoseed spectrum and were easily ignored using the dose threshold.
The single seed depth dose profile, as collected by the new probe closely matched
the TG-43U1 calculation. Any uncertainty seen in that data can be attributed to
the positioning of the seed relative to the probe. In the future the eye phantom
single seed cap will be employed to improve the accuracy of measurements.
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Full plaque measurements utilising the sterilisation inserts of the eye phantom
and the new probe showed a fair agreement with the TG-43U1 calculation. In
determining the angular effects of the probe, it can be concluded that there is a
slight dependence in distances lower than approximately 3 mm. However further
investigation was required with higher activity sources, as the statistics collected in
this experiment were low.
The eye plaque brachytherapy QA system developed by the CMRP can be used
clinically for dose rate verification of eye plaques prior to their insertion within a
patient. This has been shown by the successful implementation of the phantom
sterility system. In addition, the system displayed the ability to detect plaque
packing errors, where incorrect seeds are loaded into either the inner- or outersections. While some uncertainties from detector localisation and the presence of an
air gap within the probe tip exist, the results from the system once calibrated closely
matched the dose of a known source and clearly registered errors when introduced.
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Chapter 9
Detector Optimisation
Although the clinical strength results performed at POW hospital were within 1% of
the planned dose in the calibration range, measurements acquired at small distances
from the plaque showed an under-response of approximately 5%. While this does not
change the efficacy of the QA system within the calibration range, an investigation
into the causes of this discrepancy was initiated. As with the classic probe, mounted
with a PIN diode, it is possible that the newly constructed probe has an angular
dependence. This could be due to the inherent shortcomings of the diode, but this
has been documented to fall within ± 2%, not the 5% evident. Other factors can
be that the shielding of the probe, or the construction of the PCB within the probe
could be contributing to an apparent angular dependence.

9.1

CT Scan

To assess the probes construction qualitatively, a CT scan was performed. This
was to characterise both the construction of the components and the position of the
diode within the probe. Figure 9.1 shows a cross-section of the probe as it is laid on
the CT bed. From this image, the position of some of the vital components within
the probe tip cannot be ascertained, however the general position of the preamplifier
and circuit board is approximately within the centre of the outer container.
The cross-sectional position of the probe tip was also investigated. A diagram
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Figure 9.1: CT image of the new probe

Figure 9.2: Diagram outlining how the position of the CT cross-section relates
to the construction of the probe
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outlining how the image relates to the construction of the probe can be seen in Figure
9.2. This proved difficult due to the amount of high-Z material present in the area
and the small dimensions of the components. To improve the spatial resolution and
reduce the impact of high-Z artifacts, the CT was set to use large exposure settings
that would not be suitable for most patients as the dose delivered to them at this
time would be very high. The CT settings required to acquire the image seen in
Figure 9.3 include:
• 550 mAs

• Pitch of 0.35 mm

• 140 kV

• FoV of 103 mm

Figure 9.3: Cross-section of new probe tip

The nickel coating of the plastic, protective sheath can be identified as the outer
circle as seen in Figure 9.3. It can be deduced from the heterogeneous intensity of
that circle that the nickel coating is not completely uniform at this position on the
101

probe, contributing to the possibility of an angular dependence. Within the outer
circle there can be seen four approximately rectangular, high intensity areas. The
larger of the two, most likely represent the position of the contacts of the PCB and
the tin solder adhering it to the main circuit board. The high intensity of the CT in
these areas suggest that radiation can be easily attenuated and scattered, perhaps
contributing to some angular dependence. However, the most significant finding
of the CT image is that the central rectangular area, that is surrounding by the
four previously identified, is most likely representative of the diode position. The
introduction of indents into the plastic probe sheath, as discussed in Chapter 5, was
to position the diode into the very centre of the probe. However, the CT image
indicates that the diode is not in the centre of the probe, but to one side.

Figure 9.4: Cross-section of new probe tip showing the spatial position of the
detector

Using ImageJT M , U.S. National Institute of Health, the position of the diode
can be quantified as seen in Figure 9.4. The image analysis determined the diode to
be approximately 0.345 mm offset from the centre of the probe, which is the same
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offset of the detector from the centre of the PCB.

9.2

Distance Corrections

It can be reasonably deduced from the above investigation that the diode is not
sitting in the centre of the probe, this directly effects the distance between the
detector volume and the radiation source. In order to correct the displacement of
the diode from the centre of the probe, the distance of the probe from the plaque
was adjusted. These distance corrections were calculated using Pythagoras’ theorem,
based on the distance from the centre of the sources to the detector along central
axis and the radial offset. Figure 9.5 shows the corrected experimental values taken
from POW clinical strength measurements.

Figure 9.5: Depth dose showing the comparison between the TPS and experimental measurements with a distance correction applied

The result of the distance correction shows a close relationship between the
TPS and experimental results. Small discrepancies between the two data sets can
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be attributed to the fact that the calibration was to 10 mm as measured by the
stage, not including the correction. In order to quantify the difference between the
experimental and theoretical values, an exponential fit was used to approximate the
dose rate that would have been present at the integer distances, the interpolated
points are shown in Figure 9.6.

Figure 9.6: Depth dose showing the comparison between the TPS and theoretical fit of experimental measurements
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Table 9.1: Corrected distances from the eye plaque to detector sensitive volume.

Original
distances
(mm)

Corrected
distances
(mm)

2.5

2.672

3

3.168

3.5

3.666

4

4.164

4.5

4.662

5

5.162

5.5

5.661

6

6.156

6.5

6.659

7

7.158

7.5

7.658

8

8.157

8.5

8.657

9

9.156

9.5

9.656

10

10.156

10.5

10.656

11

11.155

11.5

11.655

12

12.155
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9.3

Discussion

It can be seen that the difference between the theoretical dose rate and experimental
is well within 2% for the full plaque measurement, which is in keeping with the
limitations of the edgeless diode. It can be reasonably ascertained that there is some
angular dependence in the new probe, as demonstrated by the shallow readings, but
that there are significant uncertainties involved in the measurement of low energy
sources such as I-125. Therefore an accurate, realistic determination of distance is
required for eye plaque brachytherapy QA using this spectroscopic dosimetry system,
followed by a precise calibration.

106

Chapter 10
Conclusion
The aim of this thesis was the development and implementation of a spectroscopic,
fast read-out dosimetry system for quality assurance of I-125 eye plaque brachytherapy and that maintained sterility so required for implantation of the plaque clinically.
This was achieved utilising edgeless diodes and 3D printer technology. Furthermore,
the use of 3D printing has allowed the system to be robust, as a large number of the
integral components can be accurately and precisely produced at a relatively low
cost. The system has been successfully verified through clinical activity testing and
through extensive computer modeling using the Geant4 toolkit.
Maintaining sterility of the plaque whilst maximising the range of clinically relevant distances for the probe to measure across was a challenge. The more protected
the plaque was from the environment, generally the thicker its case would have to
be. However, the 3D printing technology allowed just 1 mm of plastic to separate
the plaque from a water environment, furthermore it protected the edgeless diode
and electronics within the new probe by just 0.5 mm.
It was found during the course of this research that the probe previously developed by the CMRP mounted with a PIN diode was not appropriate for use in eye
plaque brachytherapy QA due the angular dependence displayed at small probe to
eye plaque distances. A number of factors contributed to this dependence such as
the presence of a ceramic scaffold and the limitations of the PIN diode itself.
It was determined that a large source of error in I-125 dosimetry and qual107

ity assurance, is the definition of distances between the dosimeter and the radiation
source. The very low energy of these LDR sources result in very steep dose gradients.
Significant deviations of measured dose-rates from theory was often a consequence
of any miscalculation of the distance between the two points. The motorised gantry
and phantom calibration cap minimised the influence of positioning errors, by introducing precision and reproducibility. Furthermore, ascertaining the exact location
of the detector position within the probe and taking into account the position of the
radioactivity within the brachytherapy seeds themselves produced more accurate
results, to within 2% of predicted.
Computer modeling using the Geant4 toolkit acted as a confirmation of experimental results and investigated the physical effects of a heterogeneous probe and
environment. Initial comparisons between the gold standard, TG-43U1 and the
Geant4 model for dose to water in a water showed small differences between the
two calculation methods. The impact of nickel paint shielding the detector from rf
radiation, proved to be minimal, contrary to Geant4 models. Most likely, the actual
thickness of the nickel layer is thinner than the 0.01 mm simulated. Despite this,
the close comparison confirmed the use of Geant4 as a legitimate simulation engine.
The technology produced in the course of this research can be applied more
broadly than just I-125 eye plaque brachytherapy quality assurance. It can be used
for dosimetry in any application utilising I-125 brachytherapy sources. It has potential to be used as a dosimeter for Palladium-103 sources with a simply recalibration
and application of a new bias potential, this is due to Pd-103 spectra and relatively
low energy emissions. The system is also not compatible with radioisotopes other
than the two mentioned. For the dose calculation system to function properly, the
spectrum must contain only low energy peaks, located in close energy proximity and
whose average energy was similar to its median energy.
The future direction of this project would be the commercialisation and clinical
implementation of the system. Development of a QA protocol in collaboration with
POW hospital.
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